10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

 (Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly report ended October 31, 2012

or

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to __________

Commission file number: 000-53595

SUNWIN STEVIA INTERNATIONAL, INC.

(Exact name of registrant as specified in charter)

NEVADA	56-2416925
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6 SHENGWANG AVE., QUFU, SHANDONG, CHINA	273100
(Address of principal executive offices)	(Zip Code)

(86) 537-4424999

(Registrant's telephone number, including area code)

NOT APPLICABLE

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes [X] No [ ]

Indicate by check mark whether the registrant has been submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer                                         [  ]	Accelerated filer                                                      [  ]
Non-accelerated filer                                           [  ]	Smaller reporting company                                    [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [  ] No [X].

Indicate the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: As of December 7, 2012 there were 173,202,803 shares of the registrant's common stock issued and outstanding.

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

FORM 10-Q

QUARTERLY PERIOD ENDED OCTOBER 31, 2012

INDEX

	Page
PART I-FINANCIAL INFORMATION
Item 1.   Financial Statements	1
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.   Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.   Controls and Procedures	24
PART II-OTHER INFORMATION
Item 1.   Legal Proceedings	25
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.   Defaults Upon Senior Securities	25
Item 4.   Mine Safety Disclosures	25
Item 5.   Other Information	25
Item 6.  Exhibits	26

i

Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results

This report contains forward-looking statements. The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. A list of factors that could cause our actual results of operations and financial condition to differ materially is set forth below, and these factors are discussed in greater detail under Item 1A – "Risk Factors" in our Annual Report on Form 10-K for the year ended April 30, 2012 as filed with the Securities and Exchange Commission:

- Our revenues have declined in the past two fiscal years and there are no assurances they will return to historic levels in future periods;

- Growing dependence on related party revenues;

- Dependence upon continued market acceptance of our stevioside products, maintaining Generally Recognized as Safe status in the United States and obtaining approval in other countries in the world that currently do not permit use of steviosides in food products;

- Competition and low barriers to entry to the market in which we sell our products;

- Our dependence on the services of our president;

- Our inability to control the cost of our raw materials;

- The limitation on our ability to receive and use our cash flows effectively as a result of restrictions on currency exchange in the PRC;

- Our operations are subject to government regulation. If we fail to comply with the applicable regulations, our ability to operate in future periods could be in jeopardy;

- The absence of various corporate governance measures which may reduce stockholders’ protections against interested director transactions, conflicts of interest and other matters;

- The effect of changes resulting from the political and economic policies of the Chinese government on our assets and operations located in the PRC;

- The impact of economic reform policies in the PRC;

- The influence of the Chinese government over the manner in which our Chinese subsidiaries must conduct our business activities;

- The impact of any natural disasters and health epidemics in China;

- Regulations relating to offshore investment activities by Chinese residents may increase the administrative burden we face and create regulatory uncertainties that may limit or adversely affect our ability to complete a business combination with PRC companies;

- The lack of various legal protections in certain agreements to which we are a party and which are material to our operations which are customarily contained in similar contracts prepared in the United States;

- Our ability to enforce our rights due to policies regarding the regulation of foreign investments in China;

- Difficulties stockholders may face who seek to enforce any judgment obtained in the United States against us, which may limit the remedies otherwise available to our stockholders;

- Our ability to comply with the United States Foreign Corrupt Practices Act which could subject us to penalties and other adverse consequences;

- Provisions of our articles of incorporation and bylaws may delay or prevent a take-over which may not be in the best interests of our stockholders;

- Our dependence on our corporate management services in the preparation of our financial statements and reports we file with the SEC.

- Adverse affects on the liquidity of our stock because it currently trades below $5.00 per share, is quoted on the OTC bulletin board, and is considered a “penny stock;” and

- The impact on our stock price due to future sales of restricted stock held by existing shareholders.

We caution that the factors described herein and other factors could cause our actual results of operations and financial condition to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

ii

INDEX OF CERTAIN DEFINED TERMS USED IN THIS REPORT

We are on a fiscal year ending April 30, as such the year ended April 30, 2012 is referred to as “fiscal 2012” and the year ending April 30, 2013 is referred to as “fiscal 2013.”  Also, the three month period ending October 31, 2012 is our second quarter and is referred to as the “second quarter of fiscal 2013”; the six month period ending October 31, 2012 is refered to as the "first six months of fiscal 2013". Likewise, the three month period ending October 31, 2011 is referred to as the “second quarter of fiscal 2012”; the six month period ending October 31, 2011is refered to as the "first six months of fiscal 2012.

When used in this report, the terms:
	-	“Sunwin”, “we”, “us” and the “Company” refers to Sunwin Stevia International, Inc., a Nevada corporation formerly known as Sunwin Neutraceuticals International, Inc., and our subsidiaries;
	-	“Sunwin Tech” refers to our wholly owned subsidiary Sunwin Tech Group, Inc., a Florida corporation;
	-	“Qufu Natural Green” refers to our wholly owned subsidiary Qufu Natural Green Engineering Co., Ltd., a Chinese limited liability company;
	-	“Sunwin Stevia International” refers to our wholly owned subsidiary Sunwin Stevia International Corp., a Florida corporation, which was converted to Sunwin USA, LLC a Delaware limited liability company in May 2009;
	-	“Sunwin USA” refers to Sunwin USA, LLC, a Delaware limited liability company, a 100% owned subsidiary;
	-	“Qufu Shengwang” refers to Qufu Shengwang Stevia Biology and Science Co., Ltd., a Chinese limited liability company. Qufu Natural Green owns a 100% interest in Qufu Shengwang; and
	-	“Qufu Shengren” refers to Qufu Shengren Pharmaceutical Co., Ltd., a Chinese limited liability company, and a wholly owned subsidiary of Qufu Natural Green.
We also use the following terms when referring to certain related and other parties:
	-	“Pharmaceutical Corporation” refers to Shandong Shengwang Pharmaceutical Co., Ltd., a Chinese limited liability company which is controlled by Mr. Laiwang Zhang,  President, Chairman and a principal shareholder of our company;
	-	"Qufu Shengwang Import and Export" refers to Qufu Shengwang Import and Export Co., Ltd., a Chinese limited liability company, controlled by Mr. Zhang;
	-	“Shandong Group” refers to Shandong Shengwang Group Co., Ltd., a Chinese limited liability company, which is controlled by Mr. Zhang,   and
	-	“WILD Flavors” refers to WILD Flavors, Inc., a Delaware corporation.

iii

PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	October 31, 2012			April 30, 2012
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	618,464		$	2,958,895
Investment in real estate held for resale		1,924,337			1,919,665
Accounts receivable, net of allowance for doubtful accounts of $903,073 and $933,678, respectively		2,368,000			2,370,573
Accounts receivable - related party		735,668			550,740
Notes receivable		58,799			105,906
Loans receivable		829,576			1,962,118
Inventories, net		4,889,869			4,305,381
Due from related party		783,507			-
Prepaid taxes		59,942			-
Prepaid expenses and other current assets		638,005			633,522
Total Current Assets		12,906,167			14,806,800
Property and equipment, net		15,820,413			14,023,368
Intangible assets		1,571,678			-
Land use rights		2,276,550			2,298,973
Total Assets	$	32,574,808		$	31,129,141
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	4,938,023		$	4,052,598
Due to related party		-			79,351
Taxes payable		-			73,327
Total Current Liabilities		4,938,023			4,205,276
STOCKHOLDERS' EQUITY:
Preferred stock, $0.001 par value; 1,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.001 par value, 200,000,000 shares authorized; 173,202,803 and 157,356,137 shares issued and outstanding as of October 31, 2012 and April 30, 2012, respectively		173,203			157,356
Additional paid-in capital		33,317,008			30,445,222
Accumulated deficit		(11,057,093	)		(8,818,978	)
Accumulated other comprehensive income		5,203,667			5,140,265
Total Stockholders' Equity		27,636,785			26,923,865
Total Liabilities and Stockholders' Equity	$	32,574,808		$	31,129,141

The accompanying notes are an integral part of these unaudited financial statements.

- 1 -

 SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 (UNAUDITED)

	For the Three Months Ended October 31,						For the Six Months Ended October 31,
	2012			2011			2012			2011
Revenues	$	2,055,847		$	2,874,189		$	4,292,395		$	5,501,240
Revenues - related party		393,837			692,981			1,404,916			914,376
Total revenues		2,449,684			3,567,170			5,697,311			6,415,616
Cost of revenues		2,049,400			2,876,034			4,639,825			5,360,624
Gross profit		400,284			691,136			1,057,486			1,054,992
Operating expenses:
Loss on disposition of property and equipment		-			674,675			-			674,675
Selling expenses		192,866			253,314			490,421			402,397
General and administrative expenses		1,571,887			482,725			2,813,920			1,734,070
Total operating expenses		1,764,753			1,410,714			3,304,341			2,811,142
Operating loss		(1,364,469	)		(719,578	)		(2,246,855	)		(1,756,150	)
Other income (expense):
Other income (expense)		(1,815	)		(57,080	)		4,651			(57,056	)
Interest income		1,796			16,264			7,533			32,493
Total other income (expense)		(19	)		(40,816	)		12,184			(24,563	)
Loss before income taxes and noncontrolling interest		(1,364,488	)		(760,394	)		(2,234,671	)		(1,780,713	)
Income taxes benefit (expense)		2,709			-			(3,444	)		-
Net loss		(1,361,779	)		(760,394	)		(2,238,115	)		(1,780,713	)
Less: loss attributable to noncontrolling interest		-			19,679			-			54,258
Net loss attributable to Sunwin Stevia International, Inc.	$	(1,361,779	)	$	(740,715	)	$	(2,238,115	)	$	(1,726,455	)
Comprehensive loss:
Net loss	$	(1,361,779	)	$	(760,394	)	$	(2,238,115	)	$	(1,780,713	)
Foreign currency translation		120,931			379,940			63,402			778,279
Total comprehensive loss	$	(1,240,848	)	$	(380,454	)	$	(2,174,713	)	$	(1,002,434	)
Net loss per common share:
Loss per share - basic and diluted	$	(0.01	)	$	(0.00	)	$	(0.01	)	$	(0.01	)
Weighted average common shares outstanding - basic and diluted		167,123,023			156,856,137			162,212,894			156,713,593

The accompanying notes are an integral part of these unaudited financial statements.

- 2 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For Six Months Ended October 31,
	2012			2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,238,115	)	$	(1,780,713	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		782,766			725,660
Amortization of intangible assets		54,196			-
Amortization of land use right		27,966			27,493
Loss on disposition of property and equipment		-			674,675
Stock issued for employee compensation		810,000			-
Stock issued for services		451,759			446,331
Allowance for doubtful accounts		(32,733	)		37,000
Changes in operating assets and liabilities:
Accounts receivable and notes receivable		88,196			7,348
Accounts receivable - related party		(182,778	)		(471,616	)
Inventories		(571,480	)		(854,439	)
Prepaid expenses and other current assets		(82,135	)		(1,265,601	)
Due from related party		(767,511	)		-
Tax receivable		(59,678	)		39,029
Accounts payable and accrued expenses		871,689			725,478
Taxes payable		(73,182	)		(116,612	)
NET CASH USED IN OPERATING ACTIVITIES		(921,040	)		(1,805,967	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash used in equity acquisition		-			(626,125	)
Purchases of property and equipment		(2,536,507	)		(418,306	)
Increase in loan receivable		(1,718	)		(7,373	)
Proceeds from loan receivable		1,134,476			50,000
NET CASH USED IN INVESTING ACTIVITIES		(1,403,749	)		(1,001,804	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of related party advances		(12,546	)		-
NET CASH USED IN FINANCING ACTIVITIES		(12,546	)		-
EFFECT OF EXCHANGE RATE CHANGES ON CASH		(3,096	)		238,459
NET CHANGE IN CASH		(2,340,431	)		(2,569,312	)
Cash at the beginning of the period		2,958,895			10,563,413
Cash at the end of the period	$	618,464		$	7,994,101
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes	$	35,092		$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Intangible assets acquired from acquisition	$	1,625,874		$	-
Shares issued for acquisition	$	1,625,874		$	-

The accompanying notes are an integral part of these unaudited financial statements.

- 3 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 - ORGANIZATION AND OPERATIONS

DESCRIPTION OF BUSINESS

Sunwin Stevia International, Inc., a Nevada corporation, and its subsidiaries are referred to in this report as “we”, “us”, “our”, or “Sunwin”.

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines and veterinary products. Substantially all of our operations are located in the People’s Republic of China (the “PRC”). We have built an integrated company with the sourcing and production capabilities designed to meet the needs of our customers.

Our operations are organized into two operating segments related to our Stevioside and Chinese Medicine product lines.

In June 2010 we elected to streamline our product offerings to focus on our core business of producing and selling stevia and other herb-based products, including herb extracts and herb medicines.  Consequently, we have exited all business activities related to our veterinary medicines and sold our 100% interest in our Shengya Veterinary Medicine subsidiary to Mr. Laiwang Zhang, our President and Chairman of the Board of Directors on July 31, 2010.  

Name change

We changed our name from Sunwin Neutraceuticals International Inc. to Sunwin Stevia International, Inc. on April 23, 2012 to more accurately reflect our business operations.

Stevioside Segment

Stevioside, whose content includes rebaudioside, is an all natural, low calorie sweetener extracted from the leaves of the stevia rebaudiana plant.  Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets.

Chinese Medicine Segment

In our Chinese Medicine Segment, we manufacture and sell a variety of traditional Chinese medicine formula extracts which are used in products made for use by both humans and animals.

Qufu Shengwang

In fiscal 2009, Qufu Natural Green acquired a 60% interest in Qufu Shengwang from its shareholder, Shandong Group, for $4,026,851. The purchase price represented 60% of the value of the net tangible assets of Qufu Shengwang as of April 30, 2008. Shandong Group is owned by Laiwang Zhang, our President and Chairman of the Board of Directors.  Qufu Shengwang manufactures and sells stevia -based fertilizers and feed additives.

On September 30, 2011, Qufu Shengwang purchased the 40% equity interest in Qufu Shengwang owned by our Korean partners, Korea Stevia Company, Limited, for $626,125 in cash, and as a result of this repurchase transaction we now own 100% equity interest in all of the net assets of our subsidiary Qufu Shengwang. Therefore, the non-controlling interest of $2,109,028 in our balance sheet as of April 30, 2012 has been eliminated to reflect our 100% interest in Qufu Shengwang. We plan to use these assets to produce bio-bacterial fertilizers from our stevia residues along with the strain and formula provided by our cooperation partner Beijing Hegeng Organic Farm Technology Co., Ltd (“Hegeng”). Our facility has an estimated annual capacity to produce 10,000 metric tons of bio-bacterial fertilizers. We expect to start production in fiscal 2013.

Qufu Shengren

In fiscal 2009, Qufu Natural Green acquired Qufu Shengren for $3,097,242. The purchase price was equal to the value of the assets of Qufu Shengren as determined by an independent asset appraisal in accordance with asset appraisal principles in the PRC. Prior to being acquired by us, Qufu Shengren was engaged in the production and distribution of bulk drugs and pharmaceuticals.  Subsequent to the acquisition, Qufu Shengren produces and distributes steviosides with a full range of grades from rebaudioside-A 10 to 98.

- 4 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Sunwin USA

In fiscal 2009, we entered into a distribution agreement with WILD Flavors to assist our 55% owned Sunwin USA in the marketing and worldwide distribution of our stevioside based sweetener products and issued WILD Flavors a 45% interest in Sunwin USA.  In exchange WILD Flavors agreed to provide Sunwin USA with sales, marketing, logistics and supply chain management, product development and regulatory services valued at $1,000,000 over a period of two years beginning on February 5, 2009.

On August 8, 2012 we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541.  The transaction closed on August 20, 2012.  On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors.The $92,541 cash payment was paid by CDI and reimbursed by us through shares as part of the terms in the consulting agreement with CDI dated May 1, 2012. The net tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of generally accepted accounting principles (“U.S. GAAP”) which require elimination of the difference between the purchase price of 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets include the product development and supply chain for onlysweet.

Under the terms of the agreement, WILD Flavors assumed certain pre-closing obligations of Sunwin USA totaling approximately $694,000, including trade accounts receivable, loans, health care and monthly expenses of an employee, potential chargebacks, bank fees and broker commissions incurred prior to the closing date.  The agreement also contained customary joint indemnification and general releases.  As a result of this transaction, we will begin consolidating the operations of Sunwin USA with ours from the date of acquisition (August 20, 2012).

In addition to the Exchange Agreement, on August 8, 2012 we entered into the following additional agreements with WILD Flavors or its affiliate:

•           We entered into an Amendment to Operating Agreement with WILD Flavors pursuant to which we are now the sole manager of Sunwin USA and certain sections of the original agreement dated April 29, 2009 were deleted as they were no longer relevant following our purchase of the minority interest in Sunwin USA described above;

•           We entered into a Termination of Distribution Agreement with WILD Flavors and Sunwin USA pursuant to which the Distribution Agreement dated February 5, 2009 was terminated; and

•           We entered into a Distributorship Agreement with WILD Procurement Gmbh, a Swiss corporation (“WILD Procurement”) which is an affiliate of WILD Flavors.  Under the terms of this agreement, we appointed WILD Procurement as a non-exclusive world-wide distributor for the resale of our stevia products.  There are no minimum purchase quantities under the agreement, and the pricing and terms of each order will be negotiated by the parties at the time each purchase order is placed.  The agreement restricts WILD Procurement from purchasing steviosides or other forms of stevia that are included in our products from sources other than our company under certain circumstances.  In addition, at such time as we desire to offer new products, we must first offer WILD Procurement the non-exclusive right to distribute those products and the parties will have 60 days to reach mutually agreeable terms.  The agreement contains certain representations by us as to the quality of the products we may sell WILD Procurement and the products’ compliance with applicable laws and good manufacturing practices, as well as customary confidentiality and indemnification provisions.

In the event WILD Procurement should fund research on stevia used in food, beverage or dietary supplement applications, and as a result of this research it develops new intellectual property, such intellectual property shall be the sole property of WILD Procurement.  In the event we should jointly fund research, any new intellectual property developed from this effort will be jointly owned and each party will have the right to use the developed intellectual property in stevia-based products.

The agreement is for an initial term of 12 months and will automatically renew for successive 12 month terms unless the agreement has been terminated by either party upon 45 days prior written notice.  There are no assurances any purchase orders will be placed under the terms of the Distribution Agreement.  The agreement may also be terminated by either party upon a material breach by the other party, or upon the filing of a bankruptcy petition, both subject to certain cure periods.  In the event the agreement is terminated, WILD Procurement has the right to continue to distribute our products on a non-exclusive basis for 24 months upon terms and conditions to be negotiated by the parties.

- 5 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. The accompanying consolidated financial statements for the interim periods presented are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented. Certain financial statement amounts relating to prior periods have been reclassified to conform to the current period presentation.

These unaudited consolidated interim financial statements should be read in conjunction with the financial statements and footnotes for the year ended April 30, 2012 included in our Form 10-K as filed with the SEC. The results of operations and cash flows for the three and six months ended October 31, 2012 are not necessarily indicative of the results of operations or cash flows which may be reported for future periods or the full fiscal year.

Our consolidated financial statements include the accounts for the parent company and all our wholly owned and majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Our subsidiaries include the following:

- Qufu Natural Green;

- Qufu Shengren;

- Qufu Shengwang; and

- Sunwin Tech.

- Sunwin USA

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates include the estimated useful lives of property and equipment, the allowance for doubtful accounts.  Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of October 31, 2012, we held $618,381 of our cash and cash equivalents with commercial banking institutions in the PRC, and $83 with banks in the United States. As of April 30, 2012, we held $2,938,981 of our cash and cash equivalents with commercial banking institution in PRC, and $19,914 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through October 31, 2012.

ACCOUNTS RECEIVABLE

Accounts receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At October 31, 2012 and April 30, 2012, the allowance for doubtful accounts was $903,073 and $933,678, respectively.

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method.

- 6 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

LONG-LIVED ASSETS

We review and evaluate on an annual basis our long-lived assets, including property and equipment and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates.

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at October 31, 2012 and April 30, 2012 amounted to $0 and $73,327, respectively, consisting primarily of VAT taxes payable.

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC Section 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC Section 820-10-35-37 to measure the fair value of our financial instruments. ASC Section 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC Section 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC Section 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Section 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.  

With the exception of derivative liabilities, we do not have any other assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at October 31, 2012 and April 30, 2012, nor were any gains or losses reported in the statement of operations that were attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the year then ended.

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC Section 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns.

- 7 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

BASIC AND DILUTED LOSS PER SHARE

Pursuant to ASC Section 260-10-45, basic income (loss) per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations.

	For Six Months Ended October 31,
	2012			2011
Numerator:
Net loss	$	(2,238,115	)	$	(1,780,713	)
Numerator for basic EPS, loss applicable to common stock holders	$	(2,238,115	)	$	(1,780,713	)
Denominator:
Denominator for basic earnings per share - weighted average number of common shares outstanding		162,212,894			156,713,593
Stock awards, options, and warrants		-			-
Denominator for diluted earnings per share - adjusted weighted average outstanding average number of common shares outstanding		162,212,894			156,713,593
Basic and diluted loss per common share:
Loss per share - basic	$	(0.01	)	$	(0.01	)
Loss per share - diluted	$	(0.01	)	$	(0.01	)

At October 31, 2012 and 2011 the effect of our outstanding common stock purchase warrants was anti-dilutive as we reported a net loss applicable to our common shareholders for both periods; additionally, outstanding purchase warrants which could have resulted in the issuance of 26,666,666 additional common shares were also anti-dilutive as the exercise price of the warrants exceeded the average market price.  As a result, basic loss per share was equal to diluted loss per share for the six months ended October 31, 2012 and 2011.

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

Our functional currency is the Chinese Renminbi (“RMB”).  In accordance with ASC 830-20-35, the financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2012	RMB 6.30 to $1.00
As of October 31, 2012	RMB 6.29 to $1.00
Six months ended October 31, 2012	RMB 6.31 to $1.00
Six months ended October 31, 2011	RMB 6.42 to $1.00

- 8 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At October 31, 2012, we had $618,381 on deposit in China, which is not insured. We have not experienced any losses in such accounts through October 31, 2012.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

STOCK BASED COMPENSATION

We account for the grant of stock, stock options, warrants and restricted stock awards in accordance with ASC Section 718, “Compensation - Stock Compensation” and the applicable provisions of ASC Section 505, “Equity”, which requires entities to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying statements of operations. Research and development costs are incurred on a project specific basis. Research and development cost were $63,158 and $1,102 for the six months ended October 31, 2012 and 2011, respectively.

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

RECENT ACCOUNTING PRONOUNCEMENTS

In July 2012, FASB issued Accounting Standards Update ("ASU") No. 2012-02, Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. ASU No. 2012-02 simplifies the guidance for testing the decline in the realizable value (impairment) of indefinite-lived intangible assets other than goodwill. ASU No. 2012-02 allows an entity the option of first performing a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. The amendments in this ASU are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted. The adoption of ASU No. 2012-02 will not have a material impact on our consolidated financial statements. 

In September 2011, the FASB issued Accounting Standards Update ("ASU") No. 2011-08, Intangibles – Goodwill and Other, which simplifies how an entity is required to test goodwill for impairment. This ASU would allow an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under the ASU, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The ASU includes a number of factors to consider in conducting the qualitative assessment.  The ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011.  Early adoption is permitted. The adoption of ASU 2011-08 did not have an impact on our consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220):Presentation of Comprehensive Income. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The presentation option under current GAAP to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity has been eliminated. The amendments in this Update should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted because compliance with amendments is already permitted. We already comply with this presentation.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

- 9 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 3 –INVESTMENT IN REAL ESTATE HELD FOR RESALE

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units are expected to be delivered by December 30, 2012. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066 due upon completion of the ownership documents and transfer of the apartment units to us.  As of October 31, 2012 and April 30, 2012, we had investment in real estate held for resale of $1,924,337 and $1,919,665, respectively.

NOTE 4 - INVENTORIES

At October 31, 2012 and April 30, 2012, inventories consisted of the following:

	October 31, 2012			April 30, 2012
	(unaudited)
Raw materials	$	1,108,952		$	844,327
Work in process		742,231			298,221
Finished goods		3,749,307			3,871,730
		5,600,490			5,014,278
Less: reserve for obsolete inventory		(710,621	)		(708,897	)
	$	4,889,869		$	4,305,381

NOTE 5 - PROPERTY AND EQUIPMENT

At October 31, 2012 and April 30, 2012, property and equipment consisted of the following:

	Estimated Life	October 31, 2012			April 30, 2012
		(unaudited)
Office Equipment	5-7 Years	$	44,712		$	44,268
Auto and Trucks	10 Years		895,978			871,897
Manufacturing Equipment	20 Years		11,422,956			11,311,505
Buildings	20 Years		10,045,835			7,177,694
Construction in Process			467,245			872,864
			22,876,726			20,278,228
Less: Accumulated Depreciation			(7,056,313	)		(6,254,860	)
		$	15,820,413		$	14,023,368

For the six months ended October 31, 2012 and 2011, depreciation expense totaled $782,766 and $725,660, respectively.

- 10 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 6 – INTANGIBLE ASSETS

Intangible assets consisted of the following:

	Estimated Life	October 31, 2012			April 30, 2012
		(unaudited)
Intangible assets	5	$	1,625,874		$	-
Less: Accumulated Amortization			(54,196	)		-
		$	1,571,678		$	-

Due to our acquisition of the remaining 45% interest of Sunwin USA originally by Wild Flavors (See Note 1), we acquired intangible assets which included the supply chain developed by Wild Flavors. For the six months ended October 31, 2012 and 2011, amortization expense amounted to $54,196 and $0, respectively.  

NOTE 7- LAND USE RIGHT

Land use right consisted of the following:

	Estimated Life	October 31, 2012			April 30, 2012
		(unaudited)
Land Use Right	41.65 Years	$	2,529,358		$	2,523,146
Less: Accumulated Amortization			(252,808	)		(224,173	)
		$	2,276,550		$	2,298,973

 For the six month periods ended October 31, 2012 and 2011, amortization expense amounted to $27,966 and $27,493, respectively.

NOTE 8 – LOAN RECEIVABLE

In December 2011, we entered into a short-term loan agreement with Shandong Anda Biotech Co., Ltd. ( "Shandong Anda"), a third party. According to the terms of the agreement, we agreed to lend Shandong Anda approximately $3,181,016 (RMB 20,000,000). The loan will be due on December 18, 2012 and bears no interest. Shandong Anda is a major supplier of stevia leaves to the Company. During the fourth quarter of fiscal 2012 Shandong Anda returned $1.5 million, and during the fourth quarter of fiscal 2013, an additional $0.8 million was repaid, and the balance of the loan was $0.8 million as of October 31, 2012.

On December 22, 2010, we loaned $500,000 to CDI China, Inc., a subsidiary of CD International Enterprises, Inc.,  and an affiliate of China Direct Investments, Inc. (“CDI”) our corporate management services provider. The loan bears interest at the rate of 3% per annum and the principal balance and accrued interest were due March 30, 2011. Part of the principal of $305,459 was repaid to us by CDI China, Inc. during fiscal 2012. At October 31, 2012, the balance of this loan was $42,087, which is comprised of $22,821 in principal and $19,266 in accrued interest. Both the principal and accrued interest are now due on demand.

NOTE 9 - RELATED PARTY TRANSACTIONS

Accounts receivable – related party

At October 31, 2012 and April 30, 2012, we reported $735,668 and $550,740 in accounts receivable – related party, respectively.  Accounts receivable – related party reflected amounts due from Qufu Shengwang Import and Export Corporation, a Chinese entity owned by our Chairman, Mr. Laiwang Zhang, for merchandise that has been delivered. Total related party revenues for the six months ended October 31, 2012 and 2011 were $1,404,916 and $914,376, respectively.

- 11 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 Due from related parties

AtOctober 31, 2012 and April 30, 2012, we report $783,507 and $0 in due from related parties.During the second quarter of fiscal 2013, we advanced $783,507 to Pharmaceutical Corporation for working capital purpose. The loan bore no interest and collateral. Pharmaceutical Corporation agrees to return the advance in the third quarter of fiscal 2013.

Due to related parties

We pay management fees to Pharmaceutical Corporation. For the six month ended October 31, 2012, we paid Pharmaceutical Corporation $417,036 for management compensation, which is included in general and administrative expense. At October 31, 2012, we owed Pharmaceutical Corporation $0 for management fee compensation.

NOTE 10 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets at October 31, 2012 and April 30, 2012 totaled $638,005 and $633,522, respectively. As of October 31, 2012, prepaid expenses and other current assets includes $418,961 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us and $219,044 for employee advances and others. We recognize prepayments in inventory as suppliers make delivery of goods, and as an expense when providers provide the services.

As of April 30, 2012, prepaid expenses and other current assets includes $517,256 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us, and $116,266 for employee advances and interest receivable.

NOTE 11 - STOCKHOLDERS' EQUITY

Common stock

At October 31, 2012, we are authorized to issue 200,000,000 shares of common stock. We had 173,202,803 and 157,356,137 shares outstanding at October 31, 2012 and April 30, 2012, respectively.

On September 14, 2012 we entered into a consulting agreement with Dore Scott Perler to perform consulting services from August 1, 2012 to July 31, 2013. According to the terms of the agreement, we agreed to pay Mr. Perler a consulting fee of 90,000 shares of our common stock each quarter. On September 27, 2012, we issued 180,000 shares of our common stock at $0.135 per share to Mr. Perler for July 2012 to December 2012 consulting services.

On August 24, 2012, our board of directors authorized our 2012 Equity Compensation Plan (the “2012 Plan”) covering 10,000,000 shares of common stock.  On August 28, 2012, we filed a registration statement on Form S-8 with the SEC covering the 2012 Plan to permit us to compensate and offer to our employees, officers, directors and consultants whose past, present and/or potential contributions to our company have been or will be important to our success, an opportunity to acquire proprietary interest in our company. On September 27, we issued 6,000,000 shares of our common stock at $0.135 per share to three employees in China as bonus.

On August 8, 2012 we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541.  The transaction closed on August 20, 2012.  On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors.The $92,541 cash payment was paid by CDI and reimbursed by us through shares as part of the terms in the terms in the consulting agreement with CDI dated May 1, 2012.

On May 1, 2012 we entered into a consulting agreement with CDI to perform consulting services for fiscal 2013 and agreed to a consulting fee of 2,500,000 shares of our common stock which includes the reimbursement of $92,541 paid by CDI to Wild Flavors on our behalf in connection with our purchase of the minority interest of Sunwin USA as described in Note 1.   On August 21, 2012, we issued 2,000,000 shares to China Direct Investments with a total value of $520,000.

- 12 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

On May 9, 2011, we issued Yefu Sun 333,328 shares of our common stock for legal services pursuant to an agreement we entered into with Mr. Sun in December 2009 and amended in March 2010.  The shares were part of our agreement to issue Mr. Sun a total of 1,000,000 shares as compensation for services over a 24 month period because there was no performance commitment at the date of the agreement. We recognized compensation expense based on the fair value of our common stock at each interim reporting date.  In connection with this share issuance, $103,332 in stock-based consulting expense was recognized during the year ended April 30, 2012.  

On April 22, 2011 we entered into a consulting agreement with  a subsidiary of CD International Enterprises, Inc., to perform consulting services for fiscal 2012 and agreed to a consulting fee of 1,500,000 shares of our common stock.  On May 6, 2011 we issued 1,000,000 shares of our common stock valued at $343,000 to CDI. On November 21, 2011 we issued another 500,000 shares of our common stock valued at $181,800 to CDI as consulting expenses pursuant to this agreement. During the year ended April 30, 2012, we recognized a total of $524,800 in stock-based consulting expenses. We recognized $183,127 in stock-based consulting expenses during the year ended April 30, 2011. These amounts are reflected in general and administrative expenses in the accompanying consolidated statements of operations.

Common stock purchase warrants

In February 2009, we issued 20,000,000 shares of our common stock at a price of $0.15 per share together with five year warrants to purchase 26,666,666 shares of common stock with an exercise price of $0.35 per share in connection with a securities purchase agreement in which subsequently Wild Flavors owned approximately 15.7% of the issued and outstanding of our common stock.  As part of the securities purchase agreement, we also entered into a stockholders agreement with Wild Flavors and certain of our stockholders, including Laiwang Zhang, Dongdong Lin, Xingyuan Li, Junzhen Zhang, Xiangsheng Kong, Weidong Chai, and Fanjun Wu who then owned approximately 34.12% of our common stock. The stockholders agreement provides that so long as Wild Flavors owns at least 4,000,000 shares of our common stock, the parties will vote or cause their shares of our common stock to be voted to elect two members of our Board of Directors designated by Wild Flavors and three members designated by our stockholders who are a party to the stockholders agreement.

Up until February 5, 2011, Wild Flavors had a right of first refusal with respect to subsequent offers, if any, by us for the sale of our securities or debt obligations. The right of first refusal did not apply with respect to certain limited exceptions, including strategic license agreements, mergers and similar acquisitions and certain option programs.

During fiscal 2012, we did not issue any shares of our common stock for the exercise of purchase warrants.

A summary of the changes to our outstanding stock warrants during the six months ended October 31, 2012 is as follows:

	Shares		Weighted Average  Exercise Price
Outstanding at April 30, 2012		26,666,666	$	0.35
Granted		-		-
Exercised		-		-
Forfeited		-		-
Warrants exercisable at October 31, 2012 (unaudited)		26,666,666	$	0.35

The following information applies to all warrants outstanding at October 31, 2012:

		Warrants Outstanding			Warrants Exercisable
Exercise Prices		Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
$	0.35	26,666,666	1.25	$0.35	26,666,666	$0.35
		26,666,666		$0.35	26,666,666	$0.35

- 13 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Additional paid in capital

On May 1, 2012 we entered into a consulting agreement with CDI to perform consulting services for fiscal 2013 and agreed to a consulting fee of 2,500,000 shares of our common stock which includes the reimbursement of $92,541 paid by CDI to Wild Flavors on our behalf in connection with our purchase of the minority interest of Sunwin USA as described in Note 1.  As of July 31, 2012, no shares had been issued and we recorded 2,000,000 shares with a total value of $520,000 as additional paid in capital.  On August 21, 2012, we issued 2,000,000 shares to CDI with a total value of $520,000 and reclassified $2,000 from additional paid in capital to common stock.

NOTE 12 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three and six months ended October 31, 2012 and 2011, we operated in two reportable business segments - (1) natural sweetener (stevioside) and (2) traditional Chinese medicines. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations.

Condensed financial information with respect to these reportable business segments for the three months ended October 31, 2012 and 2011 is as follows:

	Chinese Medicines					Stevioside						Corporate and Other						Consolidated
(Unaudited)	2012		2011			2012			2011			2012			2011			2012			2011
Net revenues	$	608,828	$	852,110		$	1,840,856		$	2,715,060		$	-		$	-		$	2,449,684		$	3,567,170
Interest income	$	66	$	4,133		$	1,730		$	8,539		$	-		$	3,592		$	1,796		$	16,264
Depreciation and amortization	$	19,710	$	19,375		$	432,896		$	355,873		$	-		$	-		$	452,606		$	375,248
Income (loss) before taxes and noncontrolling interest	$	95,503	$	(170,331	)	$	(540,814	)	$	(571,031	)	$	(919,177	)	$	(19,032	)	$	(1,364,4888	)	$	(760,394	)
Segment assets	$	3,041,519	$	9,647,926		$	29,481,629		$	22,443,029		$	51,660		$	471,582		$	32,574,808		$	32,562,537

Condensed financial information with respect to these reportable business segments for the six months ended October 31, 2012 and 2011 is as follows:

	Chinese Medicines					Stevioside						Corporate and Other						Consolidated
(Unaudited)	2012		2011			2012			2011			2012			2011			2012			2011
Net revenues	$	1,364,300	$	1,609,425		$	4,333,011		$	4,806,191		$	-		$	-		$	5,697,311		$	6,415,616
Interest income	$	66	$	6,139		$	5,749		$	18,981		$	1,718		$	7,373		$	7,533		$	32,493
Depreciation and amortization	$	39,386	$	38,762		$	825,542		$	714,391		$	-		$	-		$	864,928		$	753,153
Income (loss) before taxes and noncontrolling interest	$	11,377	$	(385,926	)	$	(689,051	)	$	(945,383	)	$	(1,556,997	)	$	(449,404	)	$	(2,234,671	)	$	(1,780,713	)
Segment assets	$	3,041,519	$	9,647,926		$	29,481,629		$	22,443,029		$	51,660		$	471,582		$	32,574,808		$	32,562,537

- 14 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 13-COMMITMENTS AND CONTINGENCIES

We lease office and manufacturing space under leases in Shandong, China that expire through 2014.

All facilities related to traditional Chinese medicine segment are leased from Pharmaceutical Corporation, a related party. The term of this lease will expire in October, 2012 and provides for annual lease payments of $23,400. We have paid the rent for this facility in fiscal 2012 which was included in the management fee we paid to Pharmaceutical Corporation during fiscal 2012. We plan to renew the lease under similar terms once our on-going negotiations are completed by January 2013. Pharmaceutical Corporation agreed to waive the lease payments due in fiscal 2011.

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units are expected to be delivered by December 30, 2012. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066, upon completion of the ownership documents and transfer of the apartment units to us.

NOTE 14 – CONCENTRATIONS AND CREDIT RISK

(i)    Customer Concentrations

Customer concentrations for the six months ended October 31, 2012 and 2011 are as follows:

	Net Sales For the Six Months Ended October 31,
	2012					2011
	Chinese Medicine			Stevioside		Chinese Medicine			Stevioside
Qingdao Shangming International Trading Co., Ltd		-			-		-			15.5	%
Qingdao RuiChi Medicine Industry Limited Company		-			-		-			24.2	%
Guangdong Tengjun Veterinary Medicine Co., Ltd		16.4	%		-		10.6	%		-
Total		16.4	%		-		10.6	%		39.7	%

(ii)    Vendor Concentrations

Vendor concentrations for the six months ended October 31, 2012 and 2011 are as follows:

	Net Purchases For the Six Months Ended October 31,
	2012						2011
	Chinese Medicine			Stevioside			Chinese Medicine			Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd		30.8	%		-			46.8	%		-
Bozhou Weitao Pharmaceutical Co., Ltd		-			-			25.9	%		-
Qufu Longheng Materials Co., Ltd		61.8	%		-			-			-
Jiuquan Jiale Biotech Co., Ltd		-			16.4	%		-			17.2	%
Zhucheng Haotian Pharmaceutical Co., Ltd		-			10.2	%		-			-
Chuzhou Hairun Stevia Technology Co., Ltd		-			18.6	%		-			-
Qingdao Runhao Stevia Technology Co., Ltd		-			14.8	%		-			-
Linyuan City Chengde Stevia Leaves Planting Cooperative		-			-			-			19.2	%
Total		92.6	%		60.0	%		72.7	%		36.4	%

- 15 -

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(iii)    Credit Risk

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and the PRC. At October 31, 2012, we had $618,381 on deposit in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash held in PRC financial institutions is not insured. We have not experienced any losses in such accounts through October 31, 2012.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

NOTE 15 - SUBSEQUENT EVENT

In December 2012, Qufu Shengren completed the construction of a new stevia extraction line in the same location of its current stevioside manufacturing facility. This line facility will apply a new stevia extraction technology to produce both high and low grade stevioside. The completion of this high tech expansion of its production facilities brings our total bulk stevia production capacity to 1, 300 metric tons including 500 metric tons of stevioside which is a stevioside extract used in the pharmaceutical industry.  We expect that the total cost of this new line will be approximately $4.7 million which has been funded from generated revenues and our working capital. We have begun trial production of our new lines and anticipate our additional production capabilities will be fully operational in the third quarter of calendar 2013.

- 16 -

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the preceding unaudited consolidated financial statements and footnotes and our 2012 Annual Report on Form 10-K for fiscal year ended April 30, 2012.

OVERVIEW

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines. Substantially all of our operations are located in the PRC. We have built an integrated company with the production and distribution capabilities designed to meet the needs of our customers.

During fiscal 2013 and 2012 our operations were organized in two operating segments related to our product lines:

- Stevioside, and

- Chinese Medicine.

Recent Developments

On July 1, 2012, Qufu Shengwang entered the Cooperation Agreement with Hegeng (Beijing) Organic Farm Technology Co, Ltd. (“Hegeng”), a Chinese manufacturer and distributor of bio-fertilizers and pesticides, to jointly develop the bio-bacterial fertilizers based on the residues from our stevia extraction. Under the Cooperation Agreement, Hegeng provides strain and formula that we apply to the stevia residues to produce bio-bacterial fertilizers in the current facility of Qufu Shengwang. The bio-bacterial fertilizers will be distributed under Qufu Shengwang’s name. We plan to start production in fiscal 2013. No additional investment in the facility would be required. Our facility has an estimated annual capacity to produce 10,000 metric tons of bio-bacterial fertilizers.

On August 20, 2012, we entered into a worldwide stevia distribution agreement with WILD Procurement Gmbh, a Swiss corporation (“WILD Procurement”) which is an affiliate of WILD Flavors. Under the terms of the agreement, WILD is granted the non exclusive worldwide right as a distributor to market and resell all stevia products manufactured by Sunwin and use of all trademarks.  In conjunction with the agreement, we purchased the minority interest in Sunwin USA previously owned by WILD Flavors for an aggregate purchase price of $1,625,874, which included a cash payment of $92,541 and 7,666,666 shares of our common stock valued at $1,533,333. In light of the new distribution agreement, the previous distribution agreement between WILD Flavors and Sunwin USA was terminated.

The acquisition of the minority interest of Sunwin USA in August 2012 will change our accounting beginning in the second quarter of fiscal 2013. Because WILD Flavors had previously maintained certain approval and veto rights and maintained other minority rights to provide for WILD Flavors to effectively participate in significant decisions that would be expected to be made in the ordinary course of business under the terms of these agreements, in accordance with FASB Accounting Standards Codification 810-10-25-5 historically we did not consolidated Sunwin USA’s operations and accounted for our interest in Sunwin USA as an equity method investment. Following the purchase of the minority interest Sunwin USA will now be consolidated with our company in our financial statements.

In December 2012, Qufu Shengren completed the construction of a new stevia extraction line in the same location of its current stevioside manufacturing facility. This line facility will apply a new stevia extraction technology to produce both high and low grade stevioside. The completion of this high tech expansion of its production facilities brings us total bulk stevia production capacity to 1,300 metric tons including 500 metric tons of steviosin which is a stevioside extract used in the pharmaceutical industry. We expect that the total cost of this new line to be approximately $4.7 million which has been funded from generated revenues and our working capital. We have begun trial production of our new line and anticipate our additional production capabilities will be fully operational in the third quarter of calendar 2013.

Stevioside Segment

Stevioside and rebaudioside are all natural low calorie sweeteners extracted from the leaves of the stevia rebaudiana plant. Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets. Stevioside can be used to replace sugar in beverages and foods, including those that require baking or cooking where synthetic chemical based sweetener replacements are not suitable.

Steviosin is a natural low calorie stevioside extract for medicinal use, containing rebaudioside A at 90% with the total steviol glycosides meeting or exceeding 95% on a dry weight basis. Steviosin is used as an alternative sweetener in the pharmaceutical production in China.

- 17 -

OnlySweet™ is an all natural, zero calorie, dietary supplement comprised of three natural ingredients, including stevioside.  

In an effort to meet the international food safety standards mandated by larger consumer product companies that we expect to target as customers in the future, we have made capital investments to enhance our manufacturing facilities, equipment and documentation systems, changed certain manufacturing processes and carried out additional personnel training in order to meet these standards.  These investments allowed us to meet the HACCP System Certification, ISO 9001:2008 Certification and ISO 22000:2005 Food Safety Certification. We obtained these certifications in November, 2010.

Chinese Medicine Segment

In our Chinese Medicine segment, we manufacture and sell approximately 354 different extracts, including traditional Chinese medicine extracts and purified extracts, which may include active parts and monomer compounds such as soy isofavone.

While this segment is currently operating at full capacity, we do not expect significant growth potential from this segment in the near future. Accordingly, we continue to evaluate alternatives to the potential disposition of the Chinese Medicine segment with the view of further streamlining our product offerings and focusing our business on producing and selling high-quality stevia products. The exit strategy we are contemplating for the Chinese Medicine segment is also been influenced by our concerns regarding the continued stagnation in revenue growth and profitability of this segment in the near future. The competition in Chinese Medicine market has strengthened over the past year. In addition, the Chinese government continues to issue more regulations covering the supply of Chinese herbal raw materials and has increased the regulatory manufacturing standards on this segment.

OUR PERFORMANCE

Three months ended October 31, 2012 compared to same period in 2011

 Our total revenues in the second quarter of fiscal 2013 decreased by 31.3%, from the same period in fiscal 2012, while our gross margin decreased to 16.3% from 19.4% over the same period in fiscal 2012.  Our sales revenues, excluding revenues from related party, decreased by 28.5% in the second quarter of fiscal 2013 as compared to the same period in fiscal 2012. Our operating expenses in the second quarter of fiscal 2013 increased by 25.1% from the comparable period in 2012. Our net loss from continuing operations for the second quarter of fiscal 2013 was $1.4 million, as compared to $0.8 million for the same period in fiscal 2012. The decrease in revenues for the third quarter of fiscal 2013 resulted from lower sales volume primarily from our lower grade stevia manufactured by our Natural Green subsidiary and also from Chinese medicine segment.

Six months ended October 31, 2012 compared to same period in 2011

Our total revenues of $5.7 million in the first six months of fiscal 2013 decreased by $0.7 million, or 11.2%, compared with the same period in fiscal 2012, while our gross margin increased to 18.6% from 16.4% over the same period in fiscal 2012. Our sales revenues, excluding revenues from related party, decreased by $1.2 million, or 22.0%, in the first six months of fiscal 2013 as compared to the same period in fiscal 2012. Our operating expenses during the first six months of fiscal 2013 increased by 17.5% compared with the same period in fiscal 2012. Our net loss from continuing operations for the first six months of fiscal 2013 was $2.2 million, compared to $1.8 million for the same period in fiscal 2012.

Our operating performance in the first six months of fiscal 2013 was driven by lower sales volume in our Chinese Medicine segment accompanied by an decrease in sales volume of lower grades stevia products in our Stevioside segment. However, the actual growth of the international market, especially the U.S. market, was behind expectations as many of our manufacturing customers have ended up with higher inventories, and have reduced their purchases of raw materials.

While we have broadened our stevia product offerings to include a number of higher quality stevia grades needed in new product formulations we are developing in collaboration with WILD Flavors and Domino Sugar to introduce to the U.S. and European food and beverage industry, the demand for higher grade stevia products has yet to materialize to the degree we had anticipated, and thus our sales volume in higher grade stevia products has remained low for the first six months of fiscal 2013. Furthermore, we continue to encounter strong competition from smaller Chinese vendors who supplied cheaper and lower grade ingredients and stevioside extracts for export to Southeast Asia. During the first six months of fiscal 2013, the decrease in sales revenues in our Chinese medicine was due primarily to lower sales volume from seasonality impact during this second quarter of fiscal 2013 (July and August are off periods) and lower pricing from fierce local competition.

- 18 -

RESULTS OF OPERATIONS

The following table summarizes our results from continuing operations for the three month periods ended October 31, 2012 and 2011: 

October 31, 2012
		Chinese Medicine				Stevioside					Corporate and other		Consolidated
Total revenues	$	608,828	100.0	%	$	1,840,856		100.0	%	$	-		2,449,684		100.0	%
Cost of revenues		472,225	77.6	%		1,577,175		85.7	%		-		2,049,400		83.7	%
Gross profit		136,603	22.4	%		263,681		14.3	%		-		400,284		16.3	%
Total operating expenses		41,199	6.8	%		804,377		43.7	%		919,177		1,764,753		72.0	%
Other income(expenses)		99	0.0	%		(118)		0.0	%		-		(19	)	0.00	%
Income (loss) before taxes and noncontrolling interest	$	95,503	15.6	%	$	(540,814	)	-29.4	%	$	(919,177	)	(1,364,488	)	-55.7	%

October 31, 2011
	Chinese Medicine					Stevioside					Corporate and other			Consolidated
Total revenues	$	852,110		100.0	%	$	2,715,060		100.0	%	$	-		$	3,567,170		100.0	%
Cost of revenues		739,113		86.7	%		2,136,921		78.7	%		-			2,876,034		80.6	%
Gross profit		112,997		13.3	%		578,139		21.3	%		-			691,136		19.4	%
Total operating expenses		226,394		26.6	%		1,161,696		42.8	%		22,624			1,410,714		39.6	%
Other income (expenses)		(56,934	)	-6.7	%		12,526		0.5	%		3,592			(40,816	)	-1.1	%
Income (loss) before taxes and noncontrolling interest	$	(170,331	)	-20.0	%	$	(571,031	)	-21.0	%	$	(19,032	)	$	(760,394	)	-21.3	%

The following table summarizes our results from continuing operations for the six month periods ended October 31, 2012 and 2011: 

October 31, 2012
		Chinese Medicine				Stevioside					Corporate and other			Consolidated
Total revenues	$	1,364,300	100.0	%	$	4,333,011		100.0	%	$	-		$	5,697,311		100.0	%
Cost of revenues		1,045,937	76.7	%		3,593,888		82.9	%		-			4,639,825		81.4	%
Gross profit		318,363	23.3	%		739,123		17.1	%		-			1,057,486		18.6	%
Total operating expenses		307,105	22.5	%		1,438,521		33.2	%		1,558,715			3,304,341		58.0	%
Other income		119	0.00	%		10,347		0.2	%		1,718			12,184		0.2	%
Loss before taxes and noncontrolling interest	$	11,377	0.8	%	$	(689,051	)	-15.9	%	$	(1,556,997	)	$	(2,234,671	)	-39.2	%

- 19 -

October 31, 2011
	Chinese Medicine					Stevioside					Corporate and other			Consolidated
Total revenues	$	1,609,425		100.0	%	$	4,806,191		100.0	%	$	-		$	6,415,616		100.0	%
Cost of revenues		1,471,105		91.4	%		3,889,519		80.9	%		-			5,360,624		83.6	%
Gross profit		138,320		8.6	%		916,672		19.1	%		-			1,054,992		16.4	%
Total operating expenses		468,230		29.1	%		1,886,135		39.2	%		456,777			2,811,142		43.8	%
Other income (expenses)		(56,016	)	-3.5	%		24,080		0.5	%		7,373			(24,563	)	-0.4	%
Loss before taxes and noncontrolling interest	$	(385,926	)	-24.0	%	$	(945,383	)	-19.7	%	$	(449,404	)	$	(1,780,713	)	-27.8	%

Revenues

Total revenues in the second quarter of fiscal 2013 decreased by $1.1 million, or 31.3%, as compared to the same period in fiscal 2012. Stevioside revenues, which comprised 75.1% and 76.1% of our revenues for the second quarter of fiscal 2013 and fiscal 2012, respectively, decreased by 32.2%, while revenues in our Chinese Medicine segment decreased by 28.6%. Within our Stevioside segment, revenues from sales to third parties decreased by 28.4% in the second quarter of fiscal 2013 from the same period in fiscal 2012, while revenues from sales to related parties decreased by 43.2% from the comparable period in fiscal 2012. We did not have any sales to related parties in our Chinese medicine segment in either period.

 During the second quarter of fiscal 2013, the lower sales revenue in our Chinese medicine segment was primarily due to approximately 24.5% of lower sales volume and approximately 35.5% were attributable to a decrease in pricing due to competitive pricing in the marketing of the products for this segment.

The overall decrease in Stevioside revenues was due primarily to lower sales volume of lower grades stevia products in the domestic market to Chinese manufacturers who use our products as raw materials. In addition, the demand growth for our intermediate and higher grade stevia products continue to be slower than anticipated in international markets, especially in the U.S., where the adoption rate for stevia in the food and beverage has been slower than expected, and in the EU, where full approval of stevia did not take place until the fourth quarter of calendar 2011. We produced 46.7 metric tons of stevioside for the second quarter of fiscal 2013 as compared to 112.9 metric tons in the same period of fiscal 2012.

Total revenues for the first six months of fiscal 2013 decreased by $0.7 million, or 11.2%, compared to the same period in fiscal 2012.Stevioside revenues, which comprised 76.1% and 74.9 % of our revenues for the first six months of fiscal 2013 and fiscal 2012, respectively, decreased by $0.5 million, or 9.9%, while Chinese Medicine revenues decreased by $0.2 million, or 15.2%.

The decrease in Stevioside revenues was driven by lower sales volume of our lower grade Stevioside products in the domestic market, accompanied by a moderate increase in sales volume of our higher grades stevia products in the export market. In addition, the demand growth for our intermediate and higher grade stevia products was slower than anticipated in international markets, especially in the U.S., where the adoption rate for stevia in the food and beverage has been slower than expected, and in the EU, where full approval of stevia did not take place until the fourth quarter of calendar 2011.We also continue to experience significant downward pressure on pricing for some of our products as some of our smaller competitors have been required to liquidate their inventory while under financial distress. We produced 133.7 metric tons of stevioside for the first six months of fiscal 2013 as compared to 135.1 metric tons during the same period in fiscal 2012

Cost of Revenues and Gross Margin

Cost of revenues in the second quarter of fiscal 2013 decreased by $0.8 million, or 28.7%, as compared to the same period in fiscal 2012. Gross margin on Stevioside segment decreased during the second quarter of fiscal 2013 to 14.3%, compared to 21.3% for the same period in fiscal 2012. The Chinese medicine gross margin increased to 22.4% in the second quarter of fiscal 2013, compared to 13.3% for the same period in fiscal 2012, primarily due to 36.1% decrease in cost of revenues. As a result, consolidated gross margin for the second quarter of fiscal 2013 decreased to 16.3%, compared to 19.4% for the same period in fiscal 2012. 

- 20 -

Cost of revenues for the first six months of fiscal 2013 decreased by $0.7 million, or 13.5%, compared to the same period in fiscal 2012. Gross margin on Stevioside segment for the first six months of fiscal 2013 was 17.1%, as compared to 19.1% for the same period in fiscal 2012.The lower gross margins for Stevioside was due primarily to lower sales volume in lower grade stevia and increased competition in both the domestic and international markets which resulted in having to charge lower prices for our products to remain competitive. Gross margin on Chinese medicine was 23.3% in the first six months fiscal 2013, compared to 8.6% for the same period in fiscal 2012. The higher gross margin for Chinese Medicines was due primarily to lower costs during the period. Since we purchase our raw materials on the spot market, we are unable to predict with any degree of certainty our raw material costs and their impact on gross margins in future periods. Our consolidated gross margin for the first six months of fiscal 2013 was 18.6%, compared to 16.4% for the same period in fiscal 2012.

Total Operating Expenses

Total operating expenses for the second quarter of fiscal 2013 increased by 25.1% from the comparable period in 2012. The increase of $1.1 million in general and administrative expenses was primarily due to $0.8 million in stock compensation expense paid to employees. Selling expenses as a percentage of revenues was 7.9% in the second quarter of fiscal 2013 as compared to 7.1% in the second quarter of 2012.

 Operating expenses increased by $0.5 million, or 17.5%, in the first six months of fiscal 2013 compared to the same period in fiscal 2012. The increase of $1.1 million in general and administrative expenses was primarily due to $0.8 million in stock compensation expense paid to employees during the second quarter of fiscal 2013.

Net Loss

Loss from continuing operations in the second quarter of fiscal 2013 was $1.4 million, compared to $0.8 million in the same period in fiscal 2012. The increase in net loss was primarily due to lower sales revenues.

Loss from continuing operations in the first six months of fiscal 2013 was $2.2 million, compared to $1.8 million for the same period in fiscal 2012. The increase was due primarily to lower sales revenues and higher general and administrative expense due to stock compensation expense paid to employees.

Our Outlook

We believe that there are significant opportunities for worldwide growth in our Stevioside segment, primarily in the U.S. and EU. For fiscal 2013 and beyond, we will continue to focus on our core business of producing and selling stevioside series products.

Some of the recent favorable trends in the stevia segment include:

  - Chinese domestic food and beverages, particularly herbal tea manufacturers and the pharmaceutical industry, have increased the use of steviosides;

  - Southeast and South Asia have renewed and increased their interest in stevia, particularly high grade stevia.

  - We were notified in November of 2011 that our stevia extracts production process has been certified organic under standards established by the USDA National Organic Program and European Commission (EC) 834/2007 and EC 889/2008 which will further expand the use of our organic stevia products in the food and beverage industry market in the US and Europe;

  - The marketing strategy to differentiate ourselves as a producer of higher quality stevia grades and product formulations through these collaboration efforts has begun to lead to growth in stevia sales volume;

  - In December 2012 we completed the construction of our new stevia extraction line with trial production underway. This new line will add additional 1,300 metric tons to our current annual production capacity; and

  - On July 1, 2012, Qufu Shengwang entered the Cooperation Agreement with Hegeng, a Chinese manufacturer and distributor of bio-fertilizers and pesticides, to jointly develop the bio-bacterial fertilizers based on the residues from our stevia extraction with production expected to commence in calendar year 2013.

Meanwhile, we are also facing challenges in competitive pricing and raw materials for fiscal 2013 and 2014. During fiscal 2013, the market prices of stevioside series were impacted by strong price competition among Chinese manufacturers. We expect the price pressure to continue in fiscal 2013 and into fiscal 2014. We anticipate the price of stevia leaves, the raw material used to produce our stevioside series products to increase in the coming harvest fall season for calendar year 2013.

- 21 -

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate sufficient cash to meet its operational cash requirements.  

At October 31, 2012 and April 30, 2012, we had working capital of $8.0 million and $10.6 million, respectively.  Our cash balance at October 31, 2012 was $0.6 million, as compared to cash of $3.0 million at April 30, 2012. Our commitments for capital expenditures in fiscal 2013 are estimated at $5.2 million, comprised of $0.5 million for last installment on apartment complex unit, which is expected to be sold during fiscal 2013, and $4.7 million estimated for completion of the construction of a new stevia extraction line, as previously discussed. We expect to satisfy these obligations from our working capital. We believe that our existing cash and cash equivalents and internally generated funds will be sufficient to cover working capital requirements and capital expenditures during the 2013 fiscal year.

Accounts receivable, net of allowance for doubtful accounts, excluding accounts receivable from related parties, decreased by less than $3,000 during the second quarter of fiscal 2013. The days’ sales outstanding in accounts receivable increased to 76 days as of October 31, 2012, as compared to 63 days as of April 30, 2012.

At October 31, 2012, loan receivable amounted to $0.8 million, which represented a decrease of $1.1 million from April 30, 2012. In December 2011, we entered into a loan agreement with Shandong Anda Biotech Co., Ltd. ( Shandong Anda), a third party. According to the terms of the agreement, we lent Shandong Anda approximately $3.1 million. The loan is due on December 18, 2012 and bears no interest. During fiscal 2012 Shandong Anda repaid $1.5 million of the loan, and during the fourth quarter of fiscal 2013 an additional $0.8 million was repaid, and the balance of the loan was $0.8 million as of October 31, 2012. During the third quarter of fiscal 2011 we also lent $0.5 million to CDI China, Inc., an affiliate of CDI, our corporate management services provider. Payment of $0.2 million was received during the third quarter of 2012. At October 31, 2012, the balance of this loan was $42,087, which is comprised of $22,821 in principal and $19,266 in accrued interest. Both the principal and accrued interest are now due on demand.

At October 31, 2012, inventories, net of reserve for obsolescence, amounted to $4.9 million, as compared to $4.3 million as of April 30, 2012. The increase was primarily due to purchases of raw materials for stevia products in anticipation of future demand.

Our accounts payable and accrued expenses increased to $4.9 million at October 31, 2012 from $4.1 million at April 30, 2012. This balance, as well as that of V.A.T. taxes payable, is subject to timing of payments for purchases related to raw material purchases made in the ordinary course of business.

Cash Flows Analysis

NET CASH FLOW USED IN OPERATING ACTIVITIES:

Net cash used in operating activities was $0.9 million during the first six months of fiscal 2013, as compared to $1.8 million during the same period in fiscal 2012. The decrease resulting from cash used in operating activities was due primarily to a $0.9 million increase in accounts payable and accrued expenses due to purchases during the quarter coupled with an $0.8 million increase in non-cash stock compensation expense paid to employees in the second quarter of 2013.

Net cash used in operating activities was $1.8 million during the first six months of fiscal 2012, as compared to net cash provided by operating activities of $1.4 million during the first six months of fiscal 2011. The decrease resulting from cash used in operating activities was due primarily to $1.3 million increase in prepaid expenses and other current assets related to advance payments for stevia raw materials and deposits for apartment units contracted for future employees under our talent search plan sponsored by our company. We also used $0.8 million of cash to purchase raw materials inventory in stevia to support future sales under our collaboration agreement with WILD Flavors and Domino Sugar.

NET CASH FLOW USED IN INVESTING ACTIVITIES:

Net cash used in investing activities amounted to $1.4 million during the first six months of fiscal 2013, as compared to $1.0 million for the same period in fiscal 2012. The increase was primarily due to $2.5 million in capital expenditures for property and equipment offset by $1.1 million in loan proceeds.

Net cash used in investing activities amounted to $1.0 million during the second quarter of fiscal 2012, as compared to $0.1 million for the same period in fiscal 2011. The increase was due primarily to $0.6 million used for the purchase of the remaining 40% equity interest in Qufu Shengwang from our Korean partners, Korea Stevia Company, Limited, and $0.4 million in capital expenditures for property and equipment during fiscal 2012.

- 22 -

NET CASH FLOW USED IN FINANCING ACTIVITIES:

Net cash used in financing activities amounted to $12,546 during the second quarter of fiscal 2013, which represented repayments of advances from related party, with no comparable amount in fiscal 2012.

CASH ALLOCATION BY COUNTRIES

The functional currency of our Chinese subsidiaries is the Chinese RMB. Substantially all of our cash is held in the form of RMB at financial institutions located in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash accounts at financial institutions in the PRC are not insured. We have not experienced any losses in such accounts as of October 31, 2012.

In 1996, the Chinese government introduced regulations which relaxed restrictions on the conversion of the RMB; however restrictions still remain, including but not limited to restrictions on foreign invested entities. Foreign invested entities may only buy, sell or remit foreign currencies after providing valid commercial documents at only those banks authorized to conduct foreign exchanges. Furthermore, the conversion of RMB for capital account items, including direct investments and loans, is subject to PRC government approval. Chinese entities are required to establish and maintain separate foreign exchange accounts for capital account items. We cannot be certain Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the RMB, especially with respect to foreign exchange transactions. Accordingly, cash on deposit in banks in the PRC is not readily deployable by us for purposes outside of the PRC. Our cash position by geographic area is as follows:

	October 31, 2012		April 30, 2012
		(Unaudited)
China	$	83	$	2,938,981
United States		618,381		19,914
Total	$	618,464	$	2,958,895

Off Balance Sheet Arrangements

Under SEC regulations, we are required to disclose our off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, such as changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. An off-balance sheet arrangement means a transaction, agreement or contractual arrangement to which any entity that is not consolidated with us as a party, under which we have:

• Any obligation under certain guarantee contracts,

• Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets,

• Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to our stock and classified in stockholder’s equity in our statement of financial position, and

• Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.

We do not have any off-balance sheet arrangements that we are required to disclose pursuant to these regulations. In the ordinary course of business, we enter into operating lease commitments, purchase commitments and other contractual obligations. These transactions are recognized in our financial statements in accordance with U.S. GAAP.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with U.S. GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of our financial condition and results of operations, and which require us to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 1 to our financial statements. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.

- 23 -

Estimates

Significant estimates for the periods reported include the allowance for doubtful accounts which is based on an evaluation of our outstanding accounts receivable including the age of amounts due, the financial condition of our specific customers and historical bad debt experience. This evaluation methodology has proven to provide a reasonable estimate of bad debt expense in the past and we intend to continue to employ this approach in our analysis of collectability.  However, we are aware that given the current global economic crises, including that of the PRC, meaningful time horizons may change.  We intend to enhance our focus on the evaluation of our customers' sustainability and adjust our estimates as may be indicted.

We rely on assumptions such as volatility, forfeiture rate, and expected dividend yield when calculating the fair value of our derivative liability related to common stock purchase warrants. We also rely on assumptions and estimates to calculate our reserve for obsolete inventory and the depreciation of property, plant and equipment. We make assumptions of expiration of our products held as inventory based on historical experience and if applicable, regulatory recommendation. We also group property plant and equipment into similar groups of assets and estimate the useful life of each group of assets.

Further, we rely on certain assumptions and calculations underlying our provision for taxes in the PRC.  Assumptions and estimates employed in these areas are material to our reported financial conditions and results of operations.  These assumptions and estimates have been materially accurate in the past and are not expected to materially change in the future.  Actual results could differ from these estimates.

Revenue recognition

We follow the guidance of ASC 605, "Revenue Recognition,” and the Securities and Exchange Commission's Staff Accounting Bulletin (“SAB”) No. 104 and SAB Topic 13 for revenue recognition. In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

Long-lived assets

We review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

 We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer,("CEO"), and our Chief Financial Officer("CFO"), to allow timely decisions regarding required disclosure.

Management, with the participation of our CEO and CFO, performed an evaluation of the effectiveness of our disclosure controls and procedures as of October 31, 2012.  

Based on this evaluation our management concluded that our disclosure controls and procedures were effective as of October 31, 2012 such that the information relating to our company, required to be disclosed in our Securities and Exchange Commission reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) is accumulated and communicated to our management, including our CEO, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation of our controls performed during the quarter ended October 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

- 24 -

PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Risk factors describing the major risks to our business can be found under Item 1A, “Risk Factors”, in our fiscal 2012 Annual Report on Form 10-K. There has been no material change in our risk factors from those previously discussed in the fiscal 2012 Annual Report on Form 10-K.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On September 14, 2012 we entered into a consulting agreement with Dore Scott Perler to perform consulting services from August 1, 2012 to July 31, 2013. According to the terms of the agreement, we agreed to pay Mr. Perler a consulting fee of 90,000 shares of our common stock each quarter. On September 27, 2012, we issued 180,000 shares of our common stock at $0.135 per share to Mr. Perler for July 2012 to December 2012 consulting services. The recipient is an accredited or otherwise sophisticated investor who had access to business and financial information on the Company.  The issuance was exempt from registration under the Securities Act of 1933 (the “Securities Act”) in reliance on an exemption provided by Section 4(2) of that act.  The terms of this Consulting Agreement are qualified in their entirety by reference to the agreement which is filed as Exhibit 10.33 to this report.

On May 1, 2012 we entered into a consulting agreement with CDI to perform consulting services for fiscal 2013 and agreed to a consulting fee of 2,500,000 shares of our common stock which includes the reimbursement of $92,541 paid by CDI to Wild Flavors on our behalf in connection with our purchase of the minority interest of Sunwin USA.   On August 21, 2012, we issued 2,000,000 shares to China Direct Investments with a total value of $520,000. The recipient is an accredited investor. The issuance was exempt from registration under the Securities Act in reliance on an exemption provided by Section 4(2) of that act.  The terms of this Consulting Agreement are qualified in their entirety by reference to the agreement which is filed as Exhibit 10.32 to this report.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.  MINE SAFETY DISCLOSURE.

     None

ITEM 5.  OTHER INFORMATION.

During the second quarter of fiscal 2013, we advanced $783,507 to Pharmaceutical Corporation for working capital purpose. Pharmaceutical Corporation agreed to return the advance in the third quarter of fiscal 2013.

- 25 -

ITEM 6.  EXHIBITS

Exhibit No.			Description of Exhibit
	2.1		Agreement and Plan of Merger dated March 28, 2012 between Sunwin International Neutraceuticals, Inc. and Sunwin Stevia International, Inc. (Incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K as filed on April 20, 2012).
	3.1		Articles of Incorporation (Incorporated by reference to the Annual Report on Form 10-KSB for the fiscal year ended April 30, 2000).
	3.2		Certificate of Amendment to Articles of Incorporation (Incorporated by reference to the Form 8-K/A as filed on July 30, 2004).
	3.3		By-Laws (Incorporated by reference to the Annual Report on Form 10-KSB for the fiscal year ended April 30, 2000).
	3.4		Articles of Merger as filed with the Secretary of State of Nevada on March 29, 2012 (Incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K as filed on April 20, 2012).
	4.1		Form of $0.65 common stock purchase warrant (Incorporated by reference to the Report on Form 8-K as filed on March 23, 2007).
	4.2		Common Stock Purchase Warrant between Sunwin International Neutraceuticals, Inc. and Wild Flavors, Inc. dated February 5, 2009 (Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K as filed on February 11, 2009).
	4.3		Stockholders Agreement dated February 5, 2009 Sunwin International Neutraceuticals, Inc., Laiwang Zhang, Dongdong Lin, Xingyuan Li, Junzhen Zhang, Xiangsheng Kong, Weidong Chai, Laiwang Zhang, Fanjun Wu and Wild Flavors, Inc. (Incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K as filed on February 11, 2009).
	4.4		2012 Equity Compensation Plan (Incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K as filed on August 24, 2012).
	10.1		Share Exchange Agreement dated April 30, 2004 between Network USA, Inc. and the stockholders of Sunwin Tech Group, Inc. (Incorporated by reference to the Report on Form 8-K as filed with on May 12, 2004).
	10.2		Stock Purchase Agreement between Sunwin Tech Group, Inc., Qufu Natural Green Engineering Company, Limited and Shandong Shengwang Pharmaceutical Group Corporation (Incorporated by reference to the Annual Report on Form 10-K for the fiscal year ended April 30, 2004).
	10.3	+	2005 Equity Compensation Plan (Incorporated by reference to the Report on Form 8-K as filed on April 28, 2005).
	10.4		Lease agreement dated October 1, 2002 between Shandong Shengwang Pharmaceutical Corporation and Qufu Natural Green Engineering Co., Ltd. (Incorporated by reference to the Annual Report on Form 10-KSB/A for the fiscal year ended April 30, 2005).
	10.5		Lease agreement dated October 6, 2002 between Qufu LuCheng Chiya Resident Commitment and Qufu Natural Green Engineering Co., Ltd. (Incorporated by reference to the Annual Report on Form 10-KSB/A for the fiscal year ended April 30, 2005).
	10.6		Lease agreement dated April 1, 2004 between Qufu ShengDa Industry Co., Ltd. and Qufu Natural Green Engineering Co., Ltd.( Incorporated by reference to the Annual Report on Form 10-KSB/A for the fiscal year ended April 30, 2005).
	10.7		Stock Purchase Agreement dated February 7, 2006 between Sunwin International Neutraceuticals, Inc., Qufu Natural Green Engineering Company and Shandong Shengwang Pharmaceutical Group Corporation (Incorporated by reference to the Quarterly Report on Form 10-QSB for the period ended January 31, 2006).
	10.8	+	2006 Equity Compensation Plan (Incorporated by reference to the Quarterly Report on Form 10-QSB for the period ended January 31, 2006).
	10.9		Consulting Agreement between China Direct Investments, Inc. and Sunwin International Neutraceuticals, Inc. dated April 22, 2011 (Incorporated by reference to the Exhibit 10.21 to the Quarterly Report on Form 10-Q for the period ended July 31, 2011).
	10.10		Acquisition Agreement by and among Qufu Natural Green Engineering Co., Ltd. and Qufu Shengwang Stevia Biology and Science Co., Ltd. and Shandong Shengwang Group, Co., Ltd. dated June 30, 2008 (Incorporated by reference to Exhibit 10.13 to the Current Report on Form 8-K as filed on July 7, 2008).
	10.11		Stock Sale And Purchase Agreement between Sunwin International Neutraceuticals, Inc. and Shandong Shengwang Group Co., Ltd. (Incorporated by reference to Exhibit 10.14 to the Current Report on Form 8-K as filed on July 7, 2008).
	10.12		Amendment to the June 30, 2008 Acquisition Agreement by and among Qufu Natural Green Engineering Co., Ltd. and Qufu Shengwang Stevia Biology and Science Co., Ltd. and Shandong Shengwang Group Co., Ltd. dated September 2, 2008. (Incorporated by reference to Exhibit 10.15 to the Current Report on Form 8-K as filed on September 8, 2008).

- 26 -

10.13	Amendment to the June 30, 2008 Stock Sale and Purchase Agreement between Sunwin International Neutraceuticals, Inc. and Shandong Shengwang Group Co., Ltd. dated September 2, 2008 (Incorporated by reference Exhibit 10.16 to the Current Report on Form 8-K as filed on September 8, 2008).
10.14	November 18, 2008 Second Amendment to Acquisition Agreement by and among Qufu Natural Green Engineering Co., Ltd. and Qufu Shengwang Stevia Biology and Science Co., Ltd. and Shandong Shengwang Group, Co., Ltd. dated as of June 30, 2008 (Incorporated by reference Exhibit 10.19 to the Current Report on Form 8-K as filed on November 26, 2008).
10.15	November 18, 2008 Second Amendment to Stock Sale And Purchase Agreement between Sunwin International Neutraceuticals, Inc. and Shandong Shengwang Group Co., Ltd. dated as of June 30, 2008 (Incorporated by reference Exhibit 10.20 to the Current Report on Form 8-K as filed on November 26, 2008).
10.16	Securities Purchase Agreement between Sunwin International Neutraceuticals, Inc. and Wild Flavors, Inc. dated February 5, 2009 (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K as filed on February 11, 2009).
10.17	Form of Operating Agreement between Sunwin International Neutraceuticals, Inc. and Wild Flavors, Inc. (Incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K as filed on February 11, 2009).
10.18	Distributorship Agreement dated February 5, 2009 among Sunwin International Neutraceuticals, Inc., Sunwin Stevia International Corp. and Wild Flavors, Inc. (Incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K as filed on February 11, 2009).
10.19	Consulting and Management Agreement between Sunwin International Neutraceuticals, Inc. and China Direct Investments, Inc. dated as of April 29, 2009. (Incorporated by reference to Exhibit 10.24 to the Annual Report on Form 10-K filed on July 29, 2009).
10.20	Stock Sale and Purchase Agreement dated June 29, 2010 among Qufu Natural Green Engineering, Shengya Veterinary Medicine Co., Ltd., and Mr. Laiwang Zhang (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on July 7, 2010).
10.21	Stock Transfer Agreement between Korea Stevia Co, Ltd. and Qufu Shengwang Stevia Biology and Science Co., Ltd. dated September 30, 2011 (Incorporated by reference to Exhibit 10.22 to the Quarterly Report on Form 10-Q for the period ended October 31, 2011).
10.22	Commercial Housing Purchase and Sale Contract between Qufu Jinxuan Real Estate Development Co., Ltd. and Qufu Natural Green Engineering Co., Ltd. dated August 25, 2011 (Incorporated by reference to Exhibit 10.23 to the Quarterly Report on Form 10-Q for the period ended October 31, 2011).
10.23	Loan Agreement dated November 18, 2011 by and between Qufu Natural Green Engineering Co., Ltd. and Shandong Shengwang Pharmaceutical Co., Ltd. (Incorporated by reference to Exhibit 10.24 to the Quarterly Report on Form 10-Q for the period ended January 31, 2012).
10.24	Supplier Agreement dated December 2, 2012 by and between Sunwin International Neutraceuticals, Inc. and Domino Foods, Inc. (Incorporated by reference to Exhibit 10.25 to the Quarterly Report on Form 10-Q for the period ended January 31, 2012).
10.25	Loan Agreement dated December 16, 2011 by and between Qufu Natural Green Engineering Co., Ltd. and Shandong Anda Bio-Tech Co., Ltd. (Incorporated by reference to Exhibit 10.26 to the Quarterly Report on Form 10-Q for the period ended January 31, 2012).
10.26	Confirmation of Amendment to Loan Agreement with Shandong Shengwang Pharmaceutical Co., Ltd. (Incorporated by reference to Exhibit 10.27 to the Quarterly Report on Form 10-Q for the period ended January 31, 2012).
10.27	Loan agreement dated December 22, 2010 between Sunwin International Neutraceuticals, Inc. and CDI China, Inc.
10.28	Cooperation Agreement dated July 1, 2012 by and between Hegeng (Beijing) Organic Farm Technology Co., Ltd. and Qufu Shengwang Stevia Biology and Science Co. Ltd. (Incorporated by reference to Exhibit 10.28 to the Annual Report on Form 10-K for the year ended April 30, 2012).
10.29	Exchange Agreement dated August 8, 2012 by and between WILD Flavors, Inc. and Sunwin Stevia International, Inc. (Incorporated by reference to Exhibit 10.29 to the Current Report on Form 8-K as filed on August 24, 2012).
10.30	Amendment to Operating Agreement dated August 8, 2012 by and between WILD Flavors, Inc. and Sunwin Stevia International, Inc. (Incorporated by reference to Exhibit 10.30 to the Current Report on Form 8-K as filed on August 24, 2012).
10.31	Termination of Distribution Agreement dated August 8, 2012 by and between WILD Flavors, Inc., Sunwin Stevia International, Inc. and Sunwin USA, LLC (Incorporated by reference to Exhibit 10.31 to the Current Report on Form 8-K as filed on August 24, 2012).
10.32	Fiscal Year 2013 Consulting Agreement (English Translation) dated May 2, 2012 between Sunwin Stevia International, Inc. and China Direct Investments, Inc.
10.33	Consulting Agreement dated September 14, 2012 between Sunwin Stevia International, Inc., and Dore Perler.*

- 27 -

	14.1	Code of Ethics (Incorporated by reference to Exhibit 14 to the Registration Statement on Form SB-2 as filed on May 27, 2005).
	21.1	Subsidiaries of the registrant.(Incorporated by reference to Exhibit 21.1 to the Annual Report on Form 10-K for the year ended April 30, 2012).
	31.1	Section 302 Certificate of the Chief Executive Officer.*
	31.2	Section 302 Certificate of Chief Financial Officer.*
	32.1	Section 906 Certificate of Chief Executive Officer and Chief Financial Officer.*
101.INS		XBRL INSTANCE DOCUMENT**
101.SCH		XBRL TAXONOMY EXTENSION SCHEMA**
101.CAL		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE**
101.DEF		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE**
101.LAB		XBRL TAXONOMY EXTENSION LABEL LINKBASE**
101.PRE		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE**

+ Management contract or compensatory plan or arrangement.

* - Filed herewith.

** - In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 to this Quarterly Report on Form 10-Q/A shall be deemed “furnished??and not “filed”.

- 28 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SUNWIN STEVIA INTERNATIONAL, INC.
Dated: December 14, 2012	By: /s/ Dongdong Lin
	Dongdong Lin,
	Chief Executive Officer
Dated: December 14, 2012	By: /s/ Fanjun Wu
	Fanjun Wu,
	Chief Financial Officer

- 29 -

EX-10.33

Exhibit 10.33

CONSULTING AGREEMENT

This CONSULTING AGREEMENT, dated as of September 14, 2012 between Sunwin Stevia International, Inc., a Nevada corporation (the “Company”), and Dore Perler (the “Consultant”).

WITNESSETH:

WHEREAS, the Company has agreed to engage the Consultantto provide the Company with sales consulting and managerial services related to the Company’s operations in North America.

WHEREAS, the Consultant has agreed to provide such services upon the terms and for the consideration described herein;

WHEREAS, the Company and theConsultant now desire to memorializetheir agreement in a formal written agreement.

NOW THEREFORE, in consideration of the mutual promises and benefits to be derived from this Agreement, the Company and the Consultant hereby agree as follows:

1.           Appointment, Services, Term.

(a)           Effective upon August 1, 2012, the Company retains Consultant to render sales consulting and services as described below to the Company for a period terminating on July31, 2013 (the “Term”).

(b)           During the Term, Consultant shall render to the Company the consulting services for marketing and sales of bulk stevia products in the regions outside China,sale of OnlySweet business with the formulas and intellectual rights, and coordinate the communications between the Company and international business partners, as well as other functions related to managerial services as shall reasonably be requested by the Board of Directors of the Company from time to time(collectively, the “Services”).

(b)           Consultant shall be required to be based in the office of the Company located in 431 Fairway Drive Suite 251, Deerfield Beach, FL, 33441 to perform his duties hereunder for a minimum of three business days weekly.

(c)           Consultant understands and acknowledges that the term of this Agreement may be terminated at any time after 30 days prior written notice, with or without cause at either Consultant’s option or Company’s option.In the event of the termination or expiration of this Agreement, Consultant shall deliver to Company all Confidential Information (as hereinafter defined) and materials, together with all copies thereof, in Consultant’s possession or under Consultant’s control and to certify in writing to Company that all of such materials have so been returned.

2.           Compensation.

(a)           The Consultant shall receive a quarterly service fee of Ninety Thousand (90,000) shares of the Company’s common stockpayable on the first business day of the following quarter (the “Compensation Shares”).To the extent permissible under Federal securities laws, the Compensation Shares shall be issued to the Consultant under the terms of the Company’s 2012 Equity Compensation Plan.  The Consultant acknowledges he has been afforded the opportunity to ask questions of, and receive answers from the officers and/or directors of the Company acting on its behalf concerning the Company and to obtain any additional information, to the extent that the Company possesses such information or can acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information furnished and has availed himself of such opportunity to the extent he considers appropriate in order to permit him to evaluate the merits and risks of an investment in the Company. The Compensation Shares will be acquired solely for the account of the Consultant for personal investment and not with a view to, or for resale in connection with, any distribution. The Consultant does not intend to dispose of all or any part of the Compensation Shares except in compliance with the provisions of the Securities Act of 1933 and applicable state securities laws.

(b)           The Consultant is not entitled to any retirement, pension, insurances and other benefits granted to employees of the Company.

(c)           The Company shall not reimburse business travel expenses incurred by the Consultant except the ones approved by the Company.

(d)           The Consultant may be entitled to performance bonus at the full discretion of the Company as the case may be.

- 1 -

(e)           The Consultant understands and agrees that (i) Consultant will not be treated as an employee of the Company for federal tax purposes; (ii) Company will not withhold on behalf of Consultant, pursuant to this Agreement, any sums for income tax, unemployment insurance, social security, or any other withholding pursuant to any law or requirement of any governmental body relating to Consultant, (iii) all of such payments, withholdings, and benefits, if any, are the sole responsibility of Consultant; and (iv) Consultant will indemnify and hold Company harmless from any and all loss or liability arising with respect to such payments, withholdings, and benefits, if any.  In the event the Internal Revenue Service or any other governmental agency should question or challenge the independent contractor status of Consultant the parties agree that Consultant and Company shall have the right to participate in any discussion or negotiation occurring with such agency or agencies, irrespective of who initiates the discussion or negotiations.

3.           Commission; Bonuses.

(a)           In the event that the Consultant has led the efforts in the sale of OnlySweet business to a third party, the Company shall payto Consultantthe commission equivalent to 5% of the total sale price.

(b)           The Consultant is entitled to the commission equivalent to 1-5% of revenuefrom the bulk stevia sales that the Consultant generates for the Company. The commission percentages vary case by case at the full discretion of the Company.

(c)           The Consultant may be entitled to receive additional compensation as determined by the Company in its discretion.

(d)           All the commission shall be paid by cash.

4.           Confidential Information.

The parties hereto recognize that the need for the Company to preserve its specialized knowledge, trade secrets, and confidential information.  The strength and goodwill of the Company is derived from the specialized knowledge, trade secrets, and confidential information generated from experience with the activities undertaken by the Company and its subsidiaries.  The disclosure of this information and knowledge to competitors would be beneficial to them and detrimental to the Company, as would the disclosure of information about the marketing practices, pricing practices, costs, profit margins, design specifications, analytical techniques, and similar items of the Company and its subsidiaries.  By reason of being a Consultant to the Company, Consultant has or will have access to, and will obtain, specialized knowledge, trade secrets and confidential information about the Company's operations and the operations of its subsidiaries, which operations extend through the United States.  Therefore, Consultant hereby agrees as follows, recognizing that the Company is relying on these agreements in entering into this Agreement:

(a)           During and after the Term, Consultant will not use, disclose to othersany confidential business information about the affairs of the Company, including but not limited to confidential information concerning the Company's products, methods, engineering designs and standards, analytical techniques, technical information, customer information, employee information, and other non-public information acquired by him in the course of his past or future services for the Company (collectively, the “Confidential Information”).

(b)           Consultant agrees to hold as the Company's property all memoranda, books, papers, letters, formulas and other data, and all copies thereof and therefrom, in any way relating to the Company's business and affairs, whether made by him or otherwise coming into his possession, and on termination of the consulting arrangements or on demand of the Company, at any time, to deliver the same to the Company within twenty four hours of such termination or demand.

5.           Indemnification.

The Company shall defend, indemnify and hold harmless Consultant against any and all expenses, liabilities, costs, risks, and threats (including, but not limited to, all expenses of defense and investigation relating thereto), arising out of or related to this Agreement.  The Company shall have no obligation to indemnify and hold Consultant harmless for any such legal or other expense, loss, claim, damage, liability, alleged damage or alleged liability resulting from the recklessness or bad faith of the Consultant in performing the Services which are the subject of this Agreement. The Company shall be responsible for and shall reimburse Consultant for all attorney’s fees or costs incurred in enforcing the indemnity obligations set forth in this paragraph. The obligations of the Company under this paragraph shall be in addition to any liability that the Company may otherwise have.  The provisions set forth in this paragraph shall survive any termination of this agreement.

- 2 -

If for any reason the foregoing indemnification is unavailable to the Consultant or insufficient to hold him harmless, then the Company shall contribute to the amount paid or payable by the Consultant as a result of such loss, claim, damage, liability, alleged damage or alleged liability in such proportion as is appropriate to reflect not only the relative benefits received by the Company and its stockholders on the one hand and the Consultant on the other hand but also the relative fault of the Company and the Consultant, as well as any relevant equitable considerations. In any instance in which the Company has indemnified the Consultant pursuant hereto and the Consultant recovers from third parties all or any part of the amount so indemnified by the Company, the Consultant shall promptly pay over to the Company the amount so recovered.  The provisions set forth in this section shall survive any termination of the authorization provided by this letter agreement.

6.           Severability.

The provisions hereof shall be considered severable in the event that any of such provisions are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable and the remaining provisions hereof shall remain enforceable to the fullest extent permitted by law.

7.           Entire Agreement; Amendment.

This Agreement contains the entire agreement between the Company and the Consultant with respect to the subject matter thereof. This Agreement may not be amended, waived, changed, modified or discharged except by an instrument in writing.

8.           Notices.

All notices, request demands and other communications hereunder shall be in writing and shall be deemed to have duly given if delivered or mailed, postage prepaid, first class as follows:

To the Company: Sunwin International Neutraceuticals, Inc. 6 Shengwang Avenue, Qufu, China 273100 ATTN:  Dongdong Lin, CEO To the Consultant: Dore Perler 9400 S.W. 49THPlace Cooper City, FL 33328

and/or to such other persons and addresses as any party shall have specified in writing to the other.

9.           Governing Law.

This Agreement shall be governed by and construed under the laws of the State of Florida.

10.           Waiver and Further Agreement.

Any waiver of any breach of any terms or conditions of this Agreement shall not operate as a waiver of any other breach of such terms or conditions or any other term or condition, nor shall any failure to enforce any provision hereof operate as a waiver of such provision or of any other provision hereof.

11.           Heading of No Effect.

The paragraph headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

SUNWIN STEVIA INTERNATIONAL , INC.

By: /s/ Dongdong Lin

Dongdong Lin

CEO

CONSULTANT

By: /s/ Dore Perler

Dore Perler

- 3 -

EX-31.1

Exhibit 31.1

Rule 13a-14(a)/15d-14(a) Certification

I, Dongdong Lin, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended October 31, 2012 of Sunwin Stevia International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

December 14, 2012	/s/ Dongdong Lin
	Dongdong Lin,
	Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

Rule 13a-14(a)/15d-14(a) Certification

I, Fanjun Wu, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended October 31, 2012 of Sunwin Stevia International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

December 14, 2012	/s/ Fanjun Wu
	Fanjun Wu,
	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Section 1350 Certification

In connection with the quarterly report of Sunwin Stevia International, Inc. (the “Company”) on Form 10-Q for the period ended October 31, 2012 as filed with the Securities and Exchange Commission (the “Report”), I, Dongdong Lin, Chief Executive Officer of the Company, and I, Fanjun Wu, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

December 14, 2012	/s/ Dongdong Lin
	Dongdong Lin,
	Chief Executive Officer
December 14, 2012	/s/ Fanjun Wu
	Fanjun Wu,
	Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Note 7- Land Use Right: Schedule of Land Use Right (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Land Use Right:

Schedule of Land Use Right

	Estimated Life	October 31, 2012	April 30, 2012
		(unaudited)
Land Use Rights, gross	41.65 Years	$   2,529,358	$   2,523,146
Less: Accumulated Amortization, Land use right		(252,808)	(224,173)
Land use rights		$   2,276,550	$   2,298,973

XML

Note 4 - Inventories: Schedule of Inventory, Current (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Raw materials		$ 844,327
Work in process		298,221
Finished goods		3,871,730
Inventories, gross		5,014,278
Reserve for obsolete inventory		(708,897)
Inventories, net	4,889,869	4,305,381
UnauditedMember
Raw materials	1,108,952
Work in process	742,231
Finished goods	3,749,307
Inventories, gross	5,600,490
Reserve for obsolete inventory	(710,621)
Inventories, net	$ 4,889,869

XML

Note 2- Summary of Significant Accounting Policies: Taxes Payable (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Taxes Payable, Current	$ 0	$ 73,327

XML

Note 14 - Concentrations and Credit Risk: Schedule of Customer Concentration (Details)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Percent of sales to Qingdao Shangming International Trading - Stevioside		15.50%
Percent of sales to Qingdao RuiChi Medicine Industry - Stevioside		24.20%
Percent of sales to Guangdong Tengjun Veterinary Medicine - Chinese Medicine	16.40%	10.60%
Total percent of sales to major customers - Chinese Medicine	16.40%	10.60%
Total percent of sales to major customers - Stevioside		39.70%

XML

Note 5 - Property and Equipment: Schedule of Plant Property and Equipment (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Office Equipment		$ 44,268
Auto and Trucks		871,897
Manufacturing Equipment		11,311,505
Buildings		7,177,694
Construction in Process		872,864
Gross Property and Equipment		20,278,228
Less: Accumulated Depreciation		(6,254,860)
Property and equipment, net	15,820,413	14,023,368
UnauditedMember
Office Equipment	44,712
Auto and Trucks	895,978
Manufacturing Equipment	11,422,956
Buildings	10,045,835
Construction in Process	467,245
Gross Property and Equipment	22,876,726
Less: Accumulated Depreciation	(7,056,313)
Property and equipment, net	$ 15,820,413

XML

Note 2- Summary of Significant Accounting Policies: Cash and Cash Equivalents (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Cash and cash equivalents held in PRC	$ 618,381	$ 2,938,981
Cash and cash equivalents held in US	$ 83	$ 19,914

XML

Note 2- Summary of Significant Accounting Policies: Research and Development (Policies)

3 Months Ended

Oct. 31, 2012

Research and Development:

Research and Development

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying statements of operations. Research and development costs are incurred on a project specific basis. Research and development cost were $63,158 and $1,102 for the six months ended October 31, 2012 and 2011, respectively.

XML

Note 6 - Intangible Assets: Schedule of Intangible Assets and Goodwill (Details) (USD $)	Oct. 31, 2012
Intangible assets	$ 1,571,678
UnauditedMember
Intangible assets, gross	1,625,874
Accumulated Amortization, Intangible assets	(54,196)
Intangible assets	$ 1,571,678

XML

Note 14 - Concentrations and Credit Risk: Schedule of Vendor Concentration (Details)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Percent of purchase from Shandong Heze Zhongshun Pharmaceutical - Chinese Medicine	30.80%	46.80%
Percent of purchase from Bozhou Weitao Pharmaceutical - Chinese Medicine		25.90%
Percent of purchase from Qufu Longheng Materials - Chinese Medicine	61.80%
Percent of purchase from Jiuquan Jiale Biotech - Stevioside	16.40%	17.20%
Percent of purchase from Zhucheng Haotian Pharmaceutical - Stevioside	10.20%
Percent of purchase from Chuzhou Hairun Stevia Technology - Stevioside	18.60%
Percent of purchase from Qingdao Runhao Stevia Technology - Stevioside	14.80%
Percent of purchase from Linyuan City Chengde Stevia Leaves Planting Cooperative - Stevioside		19.20%
Total percent of purchase from major suppliers - Chinese Medicine	92.60%	72.70%
Total percent of purchase from major suppliers - Stevioside	60.00%	36.40%

XML

Note 2- Summary of Significant Accounting Policies: Long-lived Assets (Policies)

3 Months Ended

Oct. 31, 2012

Long-lived Assets:

Long-lived Assets

LONG-LIVED ASSETS

We review and evaluate on an annual basis our long-lived assets, including property and equipment and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates.

XML

Note 2- Summary of Significant Accounting Policies: Foreign Currency Translation (Details)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Apr. 30, 2012
Foreign Currency Exchange Rate, Translation	6.29		6.30
Average exchange rates	6.31	6.42

XML

Note 12 - Segment Information: Schedule Segment Revenues - Three Month (Tables)

3 Months Ended

Oct. 31, 2012

Schedule Segment Revenues - Three Month:

Schedule Segment Revenues - Three Month

	Chinese Medicines		Stevioside		Corporate and Other		Consolidated
(Unaudited)	2012	2011	2012	2011	2012	2011	2012	2011
Net revenues	$              608,828	$              852,110	$              1,840,856	$              2,715,060	$              -	$              -	$              2,449,684	$              3,567,170
Interest income	$              66	$              4,133	$              1,730	$              8,539	$              -	$              3,592	$              1,796	$              16,264
Depreciation and amortization	$              19,710	$              19,375	$              432,896	$              355,873	$              -	$              -	$              452,606	$              375,248
Income (loss) before taxes and noncontrolling interest	$              95,503	$               (170,331)	$              (540,814)	$              (571,031)	$              (919,177)	$              (19,032)	$              (1,364,488)	$              (760,394)
Segment assets	$              3,041,519	$              9,647,926	$              29,481,629	$              22,443,029	$              51,660	$              471,582	$              32,574,808	$              32,562,537

XML

Note 5 - Property and Equipment: Schedule of Plant Property and Equipment (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Plant Property and Equipment:

Schedule of Plant Property and Equipment

	Estimated Life	October 31, 2012	April 30, 2012
		(unaudited)
Office Equipment	5-7 Years	$          44,712	$          44,268
Auto and Trucks	10 Years	895,978	871,897
Manufacturing Equipment	20 Years	11,422,956	11,311,505
Buildings	20 Years	10,045,835	7,177,694
Construction in Process		467,245	872,864
Gross Property and Equipment		22,876,726	20,278,228
Less: Accumulated Depreciation		(7,056,313)	(6,254,860)
Property and equipment, net		$  15,820,413	$  14,023,368

XML

Note 2- Summary of Significant Accounting Policies: Research and Development (Details) (USD $)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Research and Development Expense	$ 63,158	$ 1,102

XML

Note 12 - Segment Information: Schedule Segment Revenues - Three Month (Details) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Oct. 31, 2011
Net revenues - Chinese Medicines	$ 608,828	$ 852,110	$ 1,364,300	$ 1,609,425
Net revenues - Stevioside	1,840,856	2,715,060	4,333,011	4,806,191
Net revenues - Consolidated	2,449,684	3,567,170	5,697,311	6,415,616
Interest income - Chinese Medicines	66	4,133	66	6,139
Interest income - Stevioside	1,730	8,539	5,749	18,981
Interest income - Corporate and Other		3,592	1,718	7,373
Interest income - Consolidated	1,796	16,264	7,533	32,493
Depreciation and amortization - Chinese Medicines	19,710	19,375	39,386	38,762
Depreciation and amortization - Stevioside	432,896	355,873	825,542	714,391
Depreciation and amortization - Consolidated	452,606	375,248	864,928	753,153
Loss before taxes and noncontrolling interest - Chinese Medicines	95,503	(170,331)	11,377	(385,926)
Loss before taxes and noncontrolling interest - Stevioside	(540,814)	(571,031)	(689,051)	(945,383)
Loss before taxes and noncontrolling interest - Corporate and Other	(919,177)	(19,032)	(1,556,997)	(449,404)
Loss before taxes and noncontrolling interest - Consolidated	(1,364,488)	(760,394)	(2,234,671)	(1,780,713)
Segment assets- Chinese Medicines	3,041,519	9,647,926	3,041,519	9,647,926
Segment assets- Stevioside	29,481,629	22,443,029	29,481,629	22,443,029
Segment assets- Corporate and Other	51,660	471,582	51,660	471,582
Segment assets- Consolidated	$ 32,574,808	$ 32,562,537	$ 32,574,808	$ 32,562,537

XML

Note 8 - Loan Receivable (Details) (USD $)	Dec. 18, 2012	Oct. 31, 2012	Dec. 22, 2010
Loan Receivable from Shandong Anda	$ 3,181,016	$ 800,000
Loan Receivable from CDI China		42,087	500,000
Loan Receivable from CDI China - Principle		22,821
Loan Receivable from CDI China - Interest		$ 19,266

XML

Note 2- Summary of Significant Accounting Policies: Accounts Receivable (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Allowance for Doubtful Accounts Receivable	$ 903,073	$ 933,678

XML

Note 5 - Property and Equipment

3 Months Ended

Oct. 31, 2012

Note 5 - Property and Equipment:

Note 5 - Property and Equipment

NOTE 5 - PROPERTY AND EQUIPMENT

At October 31, 2012 and April 30, 2012, property and equipment consisted of the following:

	Estimated Life	October 31, 2012	April 30, 2012
		(unaudited)
Office Equipment	5-7 Years	$          44,712	$          44,268
Auto and Trucks	10 Years	895,978	871,897
Manufacturing Equipment	20 Years	11,422,956	11,311,505
Buildings	20 Years	10,045,835	7,177,694
Construction in Process		467,245	872,864
Gross Property and Equipment		22,876,726	20,278,228
Less: Accumulated Depreciation		(7,056,313)	(6,254,860)
Property and equipment, net		$  15,820,413	$  14,023,368

For the six months ended October 31, 2012 and 2011, depreciation expense totaled $782,766 and $725,660, respectively.

XML

Note 9 - Related Party Transactions (Details) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Oct. 31, 2011	Apr. 30, 2012
Accounts receivable - related party	$ 735,668		$ 735,668		$ 550,740
Revenues - related party	393,837	692,981	1,404,916	914,376
Due from Related Parties	783,507		783,507		0
Management fees paid to Pharmaceutical Corporation			417,036
Management fees due to Pharmaceutical Corporation	$ 0		$ 0

XML

Note 12 - Segment Information: Schedule Segment Revenues - Six Month (Tables)

3 Months Ended

Oct. 31, 2012

Schedule Segment Revenues - Six Month:

Schedule Segment Revenues - Six Month

	Chinese Medicines		Stevioside		Corporate and Other		Consolidated
(Unaudited)	2012	2011	2012	2011	2012	2011	2012	2011
Net revenues	$              1,364,300	$              1,609,425	$              4,333,011	$              4,806,191	$              -	$              -	$              5,697,311	$              6,415,616
Interest income	$              66	$              6,139	$              5,749	$              18,981	$              1,718	$              7,373	$              7,533	$              32,493
Depreciation and amortization	$              39,386	$              38,762	$              825,542	$              714,391	$              -	$              -	$              864,928	$              753,153
Income (loss) before taxes and noncontrolling interest	$              11,377	$               (385,926)	$              (689,051)	$              (945,383)	$              (1,556,997)	$              (449,404)	$              (2,234,671)	$              (1,780,713)
Segment assets	$              3,041,519	$              9,647,926	$              29,481,629	$              22,443,029	$              51,660	$               471,582	$              32,574,808	$              32,562,537

XML

Note 2- Summary of Significant Accounting Policies: Basic and Diluted Loss Per Share (Policies)

3 Months Ended

Oct. 31, 2012

Basic and Diluted Loss Per Share:

Basic and Diluted Loss Per Share

BASIC AND DILUTED LOSS PER SHARE

Pursuant to ASC Section 260-10-45, basic income (loss) per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations.

	For Six Months Ended October 31,
	2012	2011
Numerator:
Net loss	$     (2,238,115)	$     (1,780,713)
Numerator for basic EPS, loss applicable to common stock holders	$     (2,238,115)	$     (1,780,713)
Denominator:
Denominator for basic earnings per share - weighted average number of common shares outstanding	162,212,894	156,713,593
Stock awards, options, and warrants	-	-
Denominator for diluted earnings per share - adjusted weighted average outstanding average number of common shares outstanding	162,212,894	156,713,593
Basic and diluted loss per common share:
Loss per share - basic	$               (0.01)	$               (0.01)
Loss per share - diluted	$               (0.01)	$               (0.01)

At October 31, 2012 and 2011 the effect of our outstanding common stock purchase warrants was anti-dilutive as we reported a net loss applicable to our common shareholders for both periods; additionally, outstanding purchase warrants which could have resulted in the issuance of 26,666,666 additional common shares were also anti-dilutive as the exercise price of the warrants exceeded the average market price.  As a result, basic loss per share was equal to diluted loss per share for the six months ended October 31, 2012 and 2011.

XML

Note 2- Summary of Significant Accounting Policies: Income Taxes (Policies)

3 Months Ended

Oct. 31, 2012

Income Taxes:

Income Taxes

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC Section 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. 

XML

Note 5 - Property and Equipment (Details) (USD $)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Depreciation expense	$ 782,766	$ 725,660

XML

Note 14 - Concentrations and Credit Risk: Schedule of Customer Concentration (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Customer Concentration:

Schedule of Customer Concentration

	Net Sales For the Six Months Ended October 31,
	2012		2011
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Qingdao Shangming International Trading Co., Ltd	-	-	-	15.5%
Qingdao RuiChi Medicine Industry Limited Company	-	-	-	24.2%
Guangdong Tengjun Veterinary Medicine Co., Ltd	16.4%	-	10.6%	-
Total	16.4%	-	10.6%	39.7%

XML

Note 2- Summary of Significant Accounting Policies: Foreign Currency Translation (Policies)

3 Months Ended

Oct. 31, 2012

Foreign Currency Translation:

Foreign Currency Translation

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

Our functional currency is the Chinese Renminbi (“RMB”).  In accordance with ASC 830-20-35, the financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2012	RMB 6.30 to $1.00
As of October 31, 2012	RMB 6.29 to $1.00
Six months ended October 31, 2012	RMB 6.31 to $1.00
Six months ended October 31, 2011	RMB 6.42 to $1.00

XML

Note 2- Summary of Significant Accounting Policies: Concentrations of Credit Risk (Policies)

3 Months Ended

Oct. 31, 2012

Concentrations of Credit Risk:

Concentrations of Credit Risk

CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At October 31, 2012, we had $618,381 on deposit in China, which is not insured. We have not experienced any losses in such accounts through October 31, 2012.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

XML

Note 4 - Inventories

3 Months Ended

Oct. 31, 2012

Note 4 - Inventories:

Note 4 - Inventories

NOTE 4 - INVENTORIES

At October 31, 2012 and April 30, 2012, inventories consisted of the following:

	October 31, 2012	April 30, 2012
	(unaudited)
Raw materials	$   1,108,952	$      844,327
Work in process	742,231	298,221
Finished goods	3,749,307	3,871,730
Inventories, gross	5,600,490	5,014,278
Less: reserve for obsolete inventory	(710,621)	(708,897)
Inventories, net	$   4,889,869	$   4,305,381

XML

Note 2- Summary of Significant Accounting Policies: Stock Based Compensation (Policies)

3 Months Ended

Oct. 31, 2012

Stock Based Compensation:

Stock Based Compensation

STOCK BASED COMPENSATION

We account for the grant of stock, stock options, warrants and restricted stock awards in accordance with ASC Section 718, “Compensation - Stock Compensation” and the applicable provisions of ASC Section 505, “Equity”, which requires entities to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation.

XML

Note 11 - Stockholders' Equity: Schedule of Changes in Outstanding Warrants (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Changes in Outstanding Warrants:

Schedule of Changes in Outstanding Warrants

	Shares	Weighted Average  Exercise Price
Outstanding at April 30, 2012	26,666,666	$             0.35
Granted	-	-
Exercised	-	-
Forfeited	-	-
Warrants exercisable at October 31, 2012 (unaudited)	26,666,666	$             0.35

XML

Note 3 -investment in Real Estate Held For Resale (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012	Dec. 08, 2011	Aug. 25, 2011
Purchase price for apartment units held for sale				$ 2,390,325
Payment of purchase price for apartment units held for sale			1,195,162	717,097
Investment in real estate held for resale	$ 1,924,337	$ 1,919,665

XML

Note 14 - Concentrations and Credit Risk (Details) (USD $)	Oct. 31, 2012
Deposits in PRC	$ 618,381

XML

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (USD $)	Oct. 31, 2012	Apr. 30, 2012
CURRENT ASSETS:
Cash and cash equivalents	$ 618,464	$ 2,958,895
Investment in real estate held for resale	1,924,337	1,919,665
Accounts receivable, net of allowance for doubtful accounts of $903,073 and $933,678, respectively	2,368,000	2,370,573
Accounts receivable - related party	735,668	550,740
Notes receivable	58,799	105,906
Loan receivable	829,576	1,962,118
Inventories, net	4,889,869	4,305,381
Due from related party	783,507
Prepaid taxes	59,942
Prepaid expenses and other current assets	638,005	633,522
Total Current Assets	12,906,167	14,806,800
Property and equipment, net	15,820,413	14,023,368
Intangible assets	1,571,678
Land use rights	2,276,550	2,298,973
Total Assets	32,574,808	31,129,141
CURRENT LIABILITIES:
Accounts payable and accrued expenses	4,938,023	4,052,598
Due to related party		79,351
Taxes payable		73,327
Total Current Liabilities	4,938,023	4,205,276
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value, 200,000,000 shares authorized; 173,202,803 shares issued and outstanding as of October 31, 2012 and Aril 30, 2012, respectively	173,203	157,356
Additional paid-in capital	33,317,008	30,445,222
Accumulated deficit	(11,057,093)	(8,818,978)
Accumulated other comprehensive income	5,203,667	5,140,265
Total Stockholders' Equity	27,636,785	26,923,865
Total Liabilities and Stockholders' Equity	$ 32,574,808	$ 31,129,141

XML

Note 14 - Concentrations and Credit Risk: Schedule of Vendor Concentration (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Vendor Concentration:

Schedule of Vendor Concentration

	Net Purchases For the Six Months Ended October 31,
	2012		2011
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd	30.8%	-	46.8%	-
Bozhou Weitao Pharmaceutical Co., Ltd	-	-	25.9%	-
Qufu Longheng Materials Co., Ltd	61.8%	-	-	-
Jiuquan Jiale Biotech Co., Ltd	-	16.4%	-	17.2%
Zhucheng Haotian Pharmaceutical Co., Ltd	-	10.2%	-	-
Chuzhou Hairun Stevia Technology Co., Ltd	-	18.6%	-	-
Qingdao Runhao Stevia Technology Co., Ltd	-	14.8%	-	-
Linyuan City Chengde Stevia Leaves Planting Cooperative	-	-	-	19.2%
Total	92.6%	60.0%	72.7%	36.4%

XML

Note 2- Summary of Significant Accounting Policies

3 Months Ended

Oct. 31, 2012

Note 2- Summary of Significant Accounting Policies:

Note 2- Summary of Significant Accounting Policies

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. The accompanying consolidated financial statements for the interim periods presented are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented. Certain financial statement amounts relating to prior periods have been reclassified to conform to the current period presentation.

These unaudited consolidated interim financial statements should be read in conjunction with the financial statements and footnotes for the year ended April 30, 2012 included in our Form 10-K as filed with the SEC. The results of operations and cash flows for the three and six months ended October 31, 2012 are not necessarily indicative of the results of operations or cash flows which may be reported for future periods or the full fiscal year.

Our consolidated financial statements include the accounts for the parent company and all our wholly owned and majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Our subsidiaries include the following:

-               Qufu Natural Green;

-               Qufu Shengren;

-               Qufu Shengwang; and

-               Sunwin Tech.

-               Sunwin USA

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates include the estimated useful lives of property and equipment, the allowance for doubtful accounts.  Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of October 31, 2012, we held $618,381 of our cash and cash equivalents with commercial banking institutions in the PRC, and $83 with banks in the United States. As of April 30, 2012, we held $2,938,981 of our cash and cash equivalents with commercial banking institution in PRC, and $19,914 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through October 31, 2012.

ACCOUNTS RECEIVABLE

Accounts receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At October 31, 2012 and April 30, 2012, the allowance for doubtful accounts was $903,073 and $933,678, respectively.

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

LONG-LIVED ASSETS

We review and evaluate on an annual basis our long-lived assets, including property and equipment and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates.

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at October 31, 2012 and April 30, 2012 amounted to $0 and $73,327, respectively, consisting primarily of VAT taxes payable.

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC Section 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC Section 820-10-35-37 to measure the fair value of our financial instruments. ASC Section 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC Section 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC Section 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Section 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.  

With the exception of derivative liabilities, we do not have any other assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at October 31, 2012 and April 30, 2012, nor were any gains or losses reported in the statement of operations that were attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the year then ended.

INCOME TAXES

We file federal and state income tax returns in the United States for our corporate operations, and file separate foreign tax returns for our Chinese subsidiaries. We account for income taxes under the provisions of ASC Section 740-10-30, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. 

BASIC AND DILUTED LOSS PER SHARE

Pursuant to ASC Section 260-10-45, basic income (loss) per common share is computed by dividing income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of us, subject to anti-dilution limitations.

	For Six Months Ended October 31,
	2012	2011
Numerator:
Net loss	$     (2,238,115)	$     (1,780,713)
Numerator for basic EPS, loss applicable to common stock holders	$     (2,238,115)	$     (1,780,713)
Denominator:
Denominator for basic earnings per share - weighted average number of common shares outstanding	162,212,894	156,713,593
Stock awards, options, and warrants	-	-
Denominator for diluted earnings per share - adjusted weighted average outstanding average number of common shares outstanding	162,212,894	156,713,593
Basic and diluted loss per common share:
Loss per share - basic	$               (0.01)	$               (0.01)
Loss per share - diluted	$               (0.01)	$               (0.01)

At October 31, 2012 and 2011 the effect of our outstanding common stock purchase warrants was anti-dilutive as we reported a net loss applicable to our common shareholders for both periods; additionally, outstanding purchase warrants which could have resulted in the issuance of 26,666,666 additional common shares were also anti-dilutive as the exercise price of the warrants exceeded the average market price.  As a result, basic loss per share was equal to diluted loss per share for the six months ended October 31, 2012 and 2011.

FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss.

Our functional currency is the Chinese Renminbi (“RMB”).  In accordance with ASC 830-20-35, the financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People’s Bank of China (the “PBOC”) or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars (“$”) was made at the following exchange rates for the respective periods:

As of April 30, 2012	RMB 6.30 to $1.00
As of October 31, 2012	RMB 6.29 to $1.00
Six months ended October 31, 2012	RMB 6.31 to $1.00
Six months ended October 31, 2011	RMB 6.42 to $1.00

CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. At October 31, 2012, we had $618,381 on deposit in China, which is not insured. We have not experienced any losses in such accounts through October 31, 2012.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

STOCK BASED COMPENSATION

We account for the grant of stock, stock options, warrants and restricted stock awards in accordance with ASC Section 718, “Compensation - Stock Compensation” and the applicable provisions of ASC Section 505, “Equity”, which requires entities to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying statements of operations. Research and development costs are incurred on a project specific basis. Research and development cost were $63,158 and $1,102 for the six months ended October 31, 2012 and 2011, respectively.

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

RECENT ACCOUNTING PRONOUNCEMENTS

In July 2012, FASB issued Accounting Standards Update ("ASU") No. 2012-02, Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. ASU No. 2012-02 simplifies the guidance for testing the decline in the realizable value (impairment) of indefinite-lived intangible assets other than goodwill. ASU No. 2012-02 allows an entity the option of first performing a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. The amendments in this ASU are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted. The adoption of ASU No. 2012-02 will not have a material impact on our consolidated financial statements. 

In September 2011, the FASB issued Accounting Standards Update ("ASU") No. 2011-08, Intangibles – Goodwill and Other, which simplifies how an entity is required to test goodwill for impairment. This ASU would allow an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under the ASU, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The ASU includes a number of factors to consider in conducting the qualitative assessment.  The ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011.  Early adoption is permitted. The adoption of ASU 2011-08 did not have an impact on our consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The presentation option under current GAAP to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity has been eliminated. The amendments in this Update should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted because compliance with amendments is already permitted. We already comply with this presentation.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

XML

Note 7- Land Use Right: Schedule of Land Use Right (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Land Use Right, gross		$ 2,523,146
Accumulated Amortization, Land Use Right		(224,173)
Land use rights	2,276,550	2,298,973
UnauditedMember
Land Use Right, gross	2,529,358
Accumulated Amortization, Land Use Right	(252,808)
Land use rights	$ 2,276,550

XML

Note 2- Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)

3 Months Ended

Oct. 31, 2012

Recent Accounting Pronouncements:

Recent Accounting Pronouncements

RECENT ACCOUNTING PRONOUNCEMENTS

In July 2012, FASB issued Accounting Standards Update ("ASU") No. 2012-02, Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. ASU No. 2012-02 simplifies the guidance for testing the decline in the realizable value (impairment) of indefinite-lived intangible assets other than goodwill. ASU No. 2012-02 allows an entity the option of first performing a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. The amendments in this ASU are effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted. The adoption of ASU No. 2012-02 will not have a material impact on our consolidated financial statements. 

In September 2011, the FASB issued Accounting Standards Update ("ASU") No. 2011-08, Intangibles – Goodwill and Other, which simplifies how an entity is required to test goodwill for impairment. This ASU would allow an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under the ASU, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The ASU includes a number of factors to consider in conducting the qualitative assessment.  The ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011.  Early adoption is permitted. The adoption of ASU 2011-08 did not have an impact on our consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The presentation option under current GAAP to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity has been eliminated. The amendments in this Update should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted because compliance with amendments is already permitted. We already comply with this presentation.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

XML

Note 11 - Stockholders' Equity: Schedule of Changes in Outstanding Warrants (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Warrants and Rights Outstanding	$ 26,666,666	$ 26,666,666
Stock Warrants Weighted Average Exercise Price	$ 0.35	$ 0.35

XML

Note 2- Summary of Significant Accounting Policies: Accounts Receivable (Policies)

3 Months Ended

Oct. 31, 2012

Accounts Receivable:

Accounts Receivable

ACCOUNTS RECEIVABLE

Accounts receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible. At October 31, 2012 and April 30, 2012, the allowance for doubtful accounts was $903,073 and $933,678, respectively.

XML

Note 4 - Inventories: Schedule of Inventory, Current (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Inventory, Current:

Schedule of Inventory, Current

	October 31, 2012	April 30, 2012
	(unaudited)
Raw materials	$   1,108,952	$      844,327
Work in process	742,231	298,221
Finished goods	3,749,307	3,871,730
Inventories, gross	5,600,490	5,014,278
Less: reserve for obsolete inventory	(710,621)	(708,897)
Inventories, net	$   4,889,869	$   4,305,381

XML

Note 2- Summary of Significant Accounting Policies: Property and Equipment (Policies)

3 Months Ended

Oct. 31, 2012

Property and Equipment:

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from five to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (“ASC”), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

XML

Note 12 - Segment Information: Schedule Segment Revenues - Six Month (Details) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Oct. 31, 2011
Net revenues - Chinese Medicines	$ 608,828	$ 852,110	$ 1,364,300	$ 1,609,425
Net revenues - Stevioside	1,840,856	2,715,060	4,333,011	4,806,191
Net revenues - Consolidated	2,449,684	3,567,170	5,697,311	6,415,616
Interest income - Chinese Medicines	66	4,133	66	6,139
Interest income - Stevioside	1,730	8,539	5,749	18,981
Interest income - Corporate and Other		3,592	1,718	7,373
Interest income - Consolidated	1,796	16,264	7,533	32,493
Depreciation and amortization - Chinese Medicines	19,710	19,375	39,386	38,762
Depreciation and amortization - Stevioside	432,896	355,873	825,542	714,391
Depreciation and amortization - Consolidated	452,606	375,248	864,928	753,153
Loss before taxes and noncontrolling interest - Chinese Medicines	95,503	(170,331)	11,377	(385,926)
Loss before taxes and noncontrolling interest - Stevioside	(540,814)	(571,031)	(689,051)	(945,383)
Loss before taxes and noncontrolling interest - Corporate and Other	(919,177)	(19,032)	(1,556,997)	(449,404)
Loss before taxes and noncontrolling interest - Consolidated	(1,364,488)	(760,394)	(2,234,671)	(1,780,713)
Segment assets- Chinese Medicines	3,041,519	9,647,926	3,041,519	9,647,926
Segment assets- Stevioside	29,481,629	22,443,029	29,481,629	22,443,029
Segment assets- Corporate and Other	51,660	471,582	51,660	471,582
Segment assets- Consolidated	$ 32,574,808	$ 32,562,537	$ 32,574,808	$ 32,562,537

XML

Note 3 -investment in Real Estate Held For Resale

3 Months Ended

Oct. 31, 2012

Note 3 -investment in Real Estate Held For Resale:

Note 3 -investment in Real Estate Held For Resale

NOTE 3 –INVESTMENT IN REAL ESTATE HELD FOR RESALE

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units are expected to be delivered by December 30, 2012. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066 due upon completion of the ownership documents and transfer of the apartment units to us.  As of October 31, 2012 and April 30, 2012, we had investment in real estate held for resale of $1,924,337 and $1,919,665, respectively.

XML

"SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Oct. 31, 2011
Revenues:
Revenues	$ 2,055,847	$ 2,874,189	$ 4,292,395	$ 5,501,240
Revenues - related party	393,837	692,981	1,404,916	914,376
Total revenues	2,449,684	3,567,170	5,697,311	6,415,616
Cost of revenues	2,049,400	2,876,034	4,639,825	5,360,624
Gross profit	400,284	691,136	1,057,486	1,054,992
Operating expenses:
Loss on disposition of property and equipment		674,675		674,675
Selling expenses	192,866	253,314	490,421	402,397
General and administrative expenses	1,571,887	482,725	2,813,920	1,734,070
Total operating expenses	1,764,753	1,410,714	3,304,341	2,811,142
Operating loss	(1,364,469)	(719,578)	(2,246,855)	(1,756,150)
Other income (expense):
Other income (expense)	(1,815)	(57,080)	4,651	(57,056)
Interest income	1,796	16,264	7,533	32,493
Total other income (expense)	(19)	(40,816)	12,184	(24,563)
Loss before income taxes and noncontrolling interest	(1,364,488)	(760,394)	(2,234,671)	(1,780,713)
Income taxes benefit (expense)	2,709		(3,444)
Net loss	(1,361,779)	(760,394)	(2,238,115)	(1,780,713)
Less: loss attributable to noncontrolling interest		19,679		54,258
Net loss attributable to Sunwin Stevia International, Inc.	(1,361,779)	(740,715)	(2,238,115)	(1,726,455)
Comprehensive loss
Net loss	(1,361,779)	(760,394)	(2,238,115)	(1,780,713)
Foreign currency translation	120,931	379,940	63,402	778,279
Total Comprehsneive loss	$ (1,240,848)	$ (380,454)	$ (2,174,713)	$ (1,002,434)
Net loss per common share:
Loss per share - basic and diluted	$ (0.01)	$ 0.00	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - basic and diluted	167,123,023	156,856,137	162,212,894	156,713,593

XML

Note 13-commitments and Contingencies

3 Months Ended

Oct. 31, 2012

Note 13-commitments and Contingencies:

Note 13-commitments and Contingencies

NOTE 13-COMMITMENTS AND CONTINGENCIES

We lease office and manufacturing space under leases in Shandong, China that expire through 2014.

All facilities related to traditional Chinese medicine segment are leased from Pharmaceutical Corporation, a related party. The term of this lease will expire in October, 2012 and provides for annual lease payments of $23,400. We have paid the rent for this facility in fiscal 2012 which was included in the management fee we paid to Pharmaceutical Corporation during fiscal 2012. We plan to renew the lease under similar terms once our on-going negotiations are completed by January 2013. Pharmaceutical Corporation agreed to waive the lease payments due in fiscal 2011.

On August 25, 2011, Qufu Natural Green entered into an agreement with Qufu Jinxuan Real Estate Development Co., Ltd., an unaffiliated third party, to purchase thirty apartment units in China for investment. The total area of the apartment complex units is 41,979 square feet, with 6,458 square feet of storage area for a total purchase price of RMB15,120,000 (approximately $2,390,325) (the “Purchase Price”). Under the terms of the agreement, the apartment units are expected to be delivered by December 30, 2012. We prepaid 30% of the Purchase Price, approximately $717,097, upon signing the agreement on August 25, 2011. An additional 50% of the Purchase Price, or approximately $1,195,162, was paid on December 8, 2011, with the balance, or approximately $478,066, upon completion of the ownership documents and transfer of the apartment units to us.

XML

Document and Entity Information (USD $)	3 Months Ended
	Oct. 31, 2012	Dec. 07, 2012
Document and Entity Information
Entity Registrant Name	SUNWIN STEVIA INTERNATIONAL, INC.
Document Type	10-Q
Document Period End Date	Oct. 31, 2012
Amendment Flag	false
Entity Central Index Key	0000806592
Current Fiscal Year End Date	--04-30
Entity Common Stock, Shares Outstanding		173,202,803
Entity Public Float	$ 17,590,714
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2

XML

Note 14 - Concentrations and Credit Risk

3 Months Ended

Oct. 31, 2012

Note 14 - Concentrations and Credit Risk:

Note 14 - Concentrations and Credit Risk

NOTE 14 – CONCENTRATIONS AND CREDIT RISK

(i)    Customer Concentrations

Customer concentrations for the six months ended October 31, 2012 and 2011 are as follows:

	Net Sales For the Six Months Ended October 31,
	2012		2011
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Qingdao Shangming International Trading Co., Ltd	-	-	-	15.5%
Qingdao RuiChi Medicine Industry Limited Company	-	-	-	24.2%
Guangdong Tengjun Veterinary Medicine Co., Ltd	16.4%	-	10.6%	-
Total	16.4%	-	10.6%	39.7%

(ii)    Vendor Concentrations

Vendor concentrations for the six months ended October 31, 2012 and 2011 are as follows:

	Net Purchases For the Six Months Ended October 31,
	2012		2011
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd	30.8%	-	46.8%	-
Bozhou Weitao Pharmaceutical Co., Ltd	-	-	25.9%	-
Qufu Longheng Materials Co., Ltd	61.8%	-	-	-
Jiuquan Jiale Biotech Co., Ltd	-	16.4%	-	17.2%
Zhucheng Haotian Pharmaceutical Co., Ltd	-	10.2%	-	-
Chuzhou Hairun Stevia Technology Co., Ltd	-	18.6%	-	-
Qingdao Runhao Stevia Technology Co., Ltd	-	14.8%	-	-
Linyuan City Chengde Stevia Leaves Planting Cooperative	-	-	-	19.2%
Total	92.6%	60.0%	72.7%	36.4%

(iii)    Credit Risk

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and the PRC. At October 31, 2012, we had $618,381 on deposit in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash held in PRC financial institutions is not insured. We have not experienced any losses in such accounts through October 31, 2012.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.

XML

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,238,115)	$ (1,780,713)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	782,766	725,660
Amortization of land use right	54,196
Amortization of intangible assets	27,966	27,493
Loss on disposition of property and equipment		674,675
Stock issued for employee compensation	810,000
Stock issued for services	451,759	446,331
Allowance for doubtful accounts	(32,733)	37,000
Changes in operating assets and liabilities:
Accounts receivable and notes receivable	88,196	7,348
Accounts receivable - related party	(182,778)	(471,616)
Inventories	(571,480)	(854,439)
Prepaid expenses and other current assets	(82,135)	(1,265,601)
Due from related party	(767,511)
Tax receivable	(59,678)	39,029
Accounts payable and accrued expenses	871,689	725,478
Taxes payable	(73,182)	(116,612)
NET CASH USED IN OPERATING ACTIVITIES	(921,040)	(1,805,967)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash used in equity acquisition		(626,125)
Purchases of property and equipment	(2,536,507)	(418,306)
Increase in loan receivable	(1,718)	(7,373)
Proceeds from loan receivable	1,134,476	50,000
NET CASH USED IN INVESTING ACTIVITIES	(1,403,749)	(1,001,804)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of related party advances	(12,546)
NET CASH USED IN FINANCING ACTIVITIES	(12,546)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(3,096)	238,459
NET CHANGE IN CASH	(2,340,431)	(2,569,312)
Cash	2,958,895	10,563,413
Cash	618,464	7,994,101
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for income taxes	35,092
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Intangible assets acquired from acquisition	$ 1,625,874
Shares issued for acquisition	1,625,874

XML

Note 8 - Loan Receivable

3 Months Ended

Oct. 31, 2012

Note 8 - Loan Receivable:

Note 8 - Loan Receivable

NOTE 8 – LOAN RECEIVABLE

In December 2011, we entered into a short-term loan agreement with Shandong Anda Biotech Co., Ltd. ( "Shandong Anda"), a third party. According to the terms of the agreement, we agreed to lend Shandong Anda approximately $3,181,016 (RMB 20,000,000). The loan will be due on December 18, 2012 and bears no interest. Shandong Anda is a major supplier of stevia leaves to the Company. During the fourth quarter of fiscal 2012 Shandong Anda returned $1.5 million, and during the fourth quarter of fiscal 2013, an additional $0.8 million was repaid, and the balance of the loan was $0.8 million as of October 31, 2012.

On December 22, 2010, we loaned $500,000 to CDI China, Inc., a subsidiary of CD International Enterprises, Inc., and an affiliate of China Direct Investments, Inc. (“CDI”) our corporate management services provider. The loan bears interest at the rate of 3% per annum and the principal balance and accrued interest were due March 30, 2011. Part of the principal of $305,459 was repaid to us by CDI China, Inc. during fiscal 2012. At October 31, 2012, the balance of this loan was $42,087, which is comprised of $22,821 in principal and $19,266 in accrued interest. Both the principal and accrued interest are now due on demand.

XML

Note 7- Land Use Right

3 Months Ended

Oct. 31, 2012

Note 7- Land Use Right:

Note 7- Land Use Right

NOTE 7- LAND USE RIGHT

Land use right consisted of the following:

	Estimated Life	October 31, 2012	April 30, 2012
		(unaudited)
Land Use Rights, gross	41.65 Years	$   2,529,358	$   2,523,146
Less: Accumulated Amortization, Land use right		(252,808)	(224,173)
Land use rights		$   2,276,550	$   2,298,973

 For the six month periods ended October 31, 2012 and 2011, amortization expense amounted to $27,966 and $27,493, respectively.

XML

Note 2- Summary of Significant Accounting Policies: Inventories (Policies)

3 Months Ended

Oct. 31, 2012

Inventories:

Inventories

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost or market (estimated net realizable value) utilizing the weighted average method.

XML

Note 15 - Subsequent Event

3 Months Ended

Oct. 31, 2012

Note 15 - Subsequent Event:

Note 15 - Subsequent Event

NOTE 15 - SUBSEQUENT EVENT

In December 2012, Qufu Shengren completed the construction of a new stevia extraction line in the same location of its current stevioside manufacturing facility. This line facility will apply a new stevia extraction technology to produce both high and low grade stevioside. The completion of this high tech expansion of its production facilities brings our total bulk stevia production capacity to 1, 300 metric tons including 500 metric tons of stevioside which is a stevioside extract used in the pharmaceutical industry.  We expect that the total cost of this new line will be approximately $4.7 million which has been funded from generated revenues and our working capital. We have begun trial production of our new lines and anticipate our additional production capabilities will be fully operational in the third quarter of calendar 2013.

XML

Note 11 - Stockholders' Equity

3 Months Ended

Oct. 31, 2012

Note 11 - Stockholders' Equity:

Note 11 - Stockholders' Equity

NOTE 11 - STOCKHOLDERS' EQUITY

Common stock

At October 31, 2012, we are authorized to issue 200,000,000 shares of common stock. We had 173,202,803 and 157,356,137 shares outstanding at October 31, 2012 and April 30, 2012, respectively.

On September 14, 2012 we entered into a consulting agreement with Dore Scott Perler to perform consulting services from August 1, 2012 to July 31, 2013. According to the terms of the agreement, we agreed to pay Mr. Perler a consulting fee of 90,000 shares of our common stock each quarter. On September 27, 2012, we issued 180,000 shares of our common stock at $0.135 per share to Mr. Perler for July 2012 to December 2012 consulting services.

On August 24, 2012, our board of directors authorized our 2012 Equity Compensation Plan (the “2012 Plan”) covering 10,000,000 shares of common stock.  On August 28, 2012, we filed a registration statement on Form S-8 with the SEC covering the 2012 Plan to permit us to compensate and offer to our employees, officers, directors and consultants whose past, present and/or potential contributions to our company have been or will be important to our success, an opportunity to acquire proprietary interest in our company. On September 27, we issued 6,000,000 shares of our common stock at $0.135 per share to three employees in China as bonus.

On August 8, 2012 we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541.  The transaction closed on August 20, 2012.  On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors. The $92,541 cash payment was paid by CDI and reimbursed by us through shares as part of the terms in the terms in the consulting agreement with CDI dated May 1, 2012.

On May 1, 2012 we entered into a consulting agreement with CDI to perform consulting services for fiscal 2013 and agreed to a consulting fee of 2,500,000 shares of our common stock which includes the reimbursement of $92,541 paid by CDI to Wild Flavors on our behalf in connection with our purchase of the minority interest of Sunwin USA as described in Note 1.   On August 21, 2012, we issued 2,000,000 shares to China Direct Investments with a total value of $520,000.

On May 9, 2011, we issued Yefu Sun 333,328 shares of our common stock for legal services pursuant to an agreement we entered into with Mr. Sun in December 2009 and amended in March 2010.  The shares were part of our agreement to issue Mr. Sun a total of 1,000,000 shares as compensation for services over a 24 month period because there was no performance commitment at the date of the agreement. We recognized compensation expense based on the fair value of our common stock at each interim reporting date.  In connection with this share issuance, $103,332 in stock-based consulting expense was recognized during the year ended April 30, 2012.  

On April 22, 2011 we entered into a consulting agreement with  a subsidiary of CD International Enterprises, Inc., to perform consulting services for fiscal 2012 and agreed to a consulting fee of 1,500,000 shares of our common stock.  On May 6, 2011 we issued 1,000,000 shares of our common stock valued at $343,000 to CDI. On November 21, 2011 we issued another 500,000 shares of our common stock valued at $181,800 to CDI as consulting expenses pursuant to this agreement. During the year ended April 30, 2012, we recognized a total of $524,800 in stock-based consulting expenses. We recognized $183,127 in stock-based consulting expenses during the year ended April 30, 2011. These amounts are reflected in general and administrative expenses in the accompanying consolidated statements of operations.

Common stock purchase warrants

In February 2009, we issued 20,000,000 shares of our common stock at a price of $0.15 per share together with five year warrants to purchase 26,666,666 shares of common stock with an exercise price of $0.35 per share in connection with a securities purchase agreement in which subsequently Wild Flavors owned approximately 15.7% of the issued and outstanding of our common stock.  As part of the securities purchase agreement, we also entered into a stockholders agreement with Wild Flavors and certain of our stockholders, including Laiwang Zhang, Dongdong Lin, Xingyuan Li, Junzhen Zhang, Xiangsheng Kong, Weidong Chai, and Fanjun Wu who then owned approximately 34.12% of our common stock. The stockholders agreement provides that so long as Wild Flavors owns at least 4,000,000 shares of our common stock, the parties will vote or cause their shares of our common stock to be voted to elect two members of our Board of Directors designated by Wild Flavors and three members designated by our stockholders who are a party to the stockholders agreement.

Up until February 5, 2011, Wild Flavors had a right of first refusal with respect to subsequent offers, if any, by us for the sale of our securities or debt obligations. The right of first refusal did not apply with respect to certain limited exceptions, including strategic license agreements, mergers and similar acquisitions and certain option programs.

During fiscal 2012, we did not issue any shares of our common stock for the exercise of purchase warrants.

A summary of the changes to our outstanding stock warrants during the six months ended October 31, 2012 is as follows:

	Shares	Weighted Average  Exercise Price
Outstanding at April 30, 2012	26,666,666	$             0.35
Granted	-	-
Exercised	-	-
Forfeited	-	-
Warrants exercisable at October 31, 2012 (unaudited)	26,666,666	$             0.35

The following information applies to all warrants outstanding at October 31, 2012:

	Warrants Outstanding			Warrants Exercisable
Exercise Prices	Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
$                     0.35	26,666,666	1.25	$                        0.35	26,666,666	$                        0.35
	26,666,666		$                        0.35	26,666,666	$                        0.35

Additional paid in capital

On May 1, 2012 we entered into a consulting agreement with CDI to perform consulting services for fiscal 2013 and agreed to a consulting fee of 2,500,000 shares of our common stock which includes the reimbursement of $92,541 paid by CDI to Wild Flavors on our behalf in connection with our purchase of the minority interest of Sunwin USA as described in Note 1.  As of July 31, 2012, no shares had been issued and we recorded 2,000,000 shares with a total value of $520,000 as additional paid in capital.  On August 21, 2012, we issued 2,000,000 shares to CDI with a total value of $520,000 and reclassified $2,000 from additional paid in capital to common stock.

XML

Note 7- Land Use Right (Details) (USD $)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Amortization expense - Land use rights	$ 27,966	$ 27,493

XML

Note 9 - Related Party Transactions

3 Months Ended

Oct. 31, 2012

Note 9 - Related Party Transactions:

Note 9 - Related Party Transactions

NOTE 9 - RELATED PARTY TRANSACTIONS

Accounts receivable – related party

At October 31, 2012 and April 30, 2012, we reported $735,668 and $550,740 in accounts receivable – related party, respectively.  Accounts receivable – related party reflected amounts due from Qufu Shengwang Import and Export Corporation, a Chinese entity owned by our Chairman, Mr. Laiwang Zhang, for merchandise that has been delivered. Total related party revenues for the six months ended October 31, 2012 and 2011 were $1,404,916 and $914,376, respectively.

 Due from related parties

At October 31, 2012 and April 30, 2012, we report $783,507 and $0 in due from related parties. During the second quarter of fiscal 2013, we advanced $783,507 to Pharmaceutical Corporation for working capital purpose. The loan bore no interest and collateral. Pharmaceutical Corporation agrees to return the advance in the third quarter of fiscal 2013.

Due to related parties

We pay management fees to Pharmaceutical Corporation. For the six month ended October 31, 2012, we paid Pharmaceutical Corporation $417,036 for management compensation, which is included in general and administrative expense. At October 31, 2012, we owed Pharmaceutical Corporation $0 for management fee compensation.

XML

Note 10 - Prepaid Expenses and Other Current Assets

3 Months Ended

Oct. 31, 2012

Note 10 - Prepaid Expenses and Other Current Assets:

Note 10 - Prepaid Expenses and Other Current Assets

NOTE 10 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets at October 31, 2012 and April 30, 2012 totaled $638,005 and $633,522, respectively. As of October 31, 2012, prepaid expenses and other current assets includes $418,961 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us and $219,044 for employee advances and others. We recognize prepayments in inventory as suppliers make delivery of goods, and as an expense when providers provide the services.

As of April 30, 2012, prepaid expenses and other current assets includes $517,256 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us, and $116,266 for employee advances and interest receivable.

XML

Note 12 - Segment Information

3 Months Ended

Oct. 31, 2012

Note 12 - Segment Information:

Note 12 - Segment Information

NOTE 12 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three and six months ended October 31, 2012 and 2011, we operated in two reportable business segments - (1) natural sweetener (stevioside) and (2) traditional Chinese medicines. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations.

Condensed financial information with respect to these reportable business segments for the three months ended October 31, 2012 and 2011 is as follows:

	Chinese Medicines		Stevioside		Corporate and Other		Consolidated
(Unaudited)	2012	2011	2012	2011	2012	2011	2012	2011
Net revenues	$              608,828	$              852,110	$              1,840,856	$              2,715,060	$              -	$              -	$              2,449,684	$              3,567,170
Interest income	$              66	$              4,133	$              1,730	$              8,539	$              -	$              3,592	$              1,796	$              16,264
Depreciation and amortization	$              19,710	$              19,375	$              432,896	$              355,873	$              -	$              -	$              452,606	$              375,248
Income (loss) before taxes and noncontrolling interest	$              95,503	$               (170,331)	$              (540,814)	$              (571,031)	$              (919,177)	$              (19,032)	$              (1,364,488)	$              (760,394)
Segment assets	$              3,041,519	$              9,647,926	$              29,481,629	$              22,443,029	$              51,660	$              471,582	$              32,574,808	$              32,562,537

Condensed financial information with respect to these reportable business segments for the six months ended October 31, 2012 and 2011 is as follows:

	Chinese Medicines		Stevioside		Corporate and Other		Consolidated
(Unaudited)	2012	2011	2012	2011	2012	2011	2012	2011
Net revenues	$              1,364,300	$              1,609,425	$              4,333,011	$              4,806,191	$              -	$              -	$              5,697,311	$              6,415,616
Interest income	$              66	$              6,139	$              5,749	$              18,981	$              1,718	$              7,373	$              7,533	$              32,493
Depreciation and amortization	$              39,386	$              38,762	$              825,542	$              714,391	$              -	$              -	$              864,928	$              753,153
Income (loss) before taxes and noncontrolling interest	$              11,377	$               (385,926)	$              (689,051)	$              (945,383)	$              (1,556,997)	$              (449,404)	$              (2,234,671)	$              (1,780,713)
Segment assets	$              3,041,519	$              9,647,926	$              29,481,629	$              22,443,029	$              51,660	$               471,582	$              32,574,808	$              32,562,537

XML

Note 11 - Stockholders' Equity (Details) (USD $)	Oct. 31, 2012	Sep. 27, 2012	Aug. 22, 2012	Aug. 21, 2012	Jul. 31, 2012	Apr. 30, 2012	Nov. 21, 2011	May 09, 2011	May 06, 2011	Apr. 30, 2011
Common stock authorized to issue	200,000,000
Shares, Outstanding	173,202,803					157,356,137
Share issued to consultant		180,000
Price per share issued to consultant		$ 0.135
Share issued to employee		6,000,000
Share issued for acquisition			7,666,666
Cash paid for acquisition			$ 92,541
Share issued to CDI				2,000,000			500,000		1,000,000
Value of shares issued to CDI				520,000			181,800		343,000
Shares issued to Yefu Sun								333,328
Stock-based consulting expense						524,800				183,127
Additional paid in capital - CDI					$ 520,000

XML

Note 11 - Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Stock Warrants Exercise Price	$ 0.35
Warrants and Rights Outstanding	$ 26,666,666	$ 26,666,666
Weighted Average Remaining Contractual Life	1.25
Stock Warrants Weighted Average Exercise Price	$ 0.35	$ 0.35
Warrants Exercisable	26,666,666
Warrants Exercisable - Weighted Average Exercise Price	$ 0.35

XML

Note 10 - Prepaid Expenses and Other Current Assets (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Prepaid expenses and other current assets	$ 638,005	$ 633,522
Prepayments to suppliers	418,961	517,256
Employee advances and others	$ 219,044	$ 116,266

XML

Note 2- Summary of Significant Accounting Policies: Revenue Recognition (Policies)

3 Months Ended

Oct. 31, 2012

Revenue Recognition:

Revenue Recognition

REVENUE RECOGNITION

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.

XML

Note 2- Summary of Significant Accounting Policies: Concentrations of Credit Risk (Details) (USD $)	Oct. 31, 2012	Apr. 30, 2012
Cash and cash equivalents held in PRC	$ 618,381	$ 2,938,981

XML

Note 2- Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)

3 Months Ended

Oct. 31, 2012

Cash and Cash Equivalents:

Cash and Cash Equivalents

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash and equivalents. As of October 31, 2012, we held $618,381 of our cash and cash equivalents with commercial banking institutions in the PRC, and $83 with banks in the United States. As of April 30, 2012, we held $2,938,981 of our cash and cash equivalents with commercial banking institution in PRC, and $19,914 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through October 31, 2012.

XML

Note 2- Summary of Significant Accounting Policies: Taxes Payable (Policies)

3 Months Ended

Oct. 31, 2012

Taxes Payable:

Taxes Payable

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales. In addition, we pay value added taxes on our primary purchases, recorded as a receivable. These amounts are presented as net amounts for financial statement purposes. Taxes payable at October 31, 2012 and April 30, 2012 amounted to $0 and $73,327, respectively, consisting primarily of VAT taxes payable.

XML

Note 2- Summary of Significant Accounting Policies: Basic and Diluted Loss Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Oct. 31, 2011
Net loss	$ (1,361,779)	$ (760,394)	$ (2,238,115)	$ (1,780,713)
Loss applicable to common stock holders			$ (2,238,115)	$ (1,780,713)
Denominator for basic earnings per share - weighted average number of common shares outstanding			162,212,894	156,713,593
Denominator for diluted earnings per share - adjusted weighted average outstanding average number of common shares outstanding			162,212,894	156,713,593
Loss per share - basic			$ (0.01)	$ (0.01)
Loss per share - diluted			$ (0.01)	$ (0.01)

XML

Note 11 - Stockholders' Equity: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Stockholders' Equity Note, Warrants or Rights:

Schedule of Stockholders' Equity Note, Warrants or Rights

	Warrants Outstanding			Warrants Exercisable
Exercise Prices	Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
$                     0.35	26,666,666	1.25	$                        0.35	26,666,666	$                        0.35
	26,666,666		$                        0.35	26,666,666	$                        0.35

XML

Note 1 - Organization and Operations

3 Months Ended

Oct. 31, 2012

Note 1 - Organization and Operations:

Note 1 - Organization and Operations

NOTE 1 - ORGANIZATION AND OPERATIONS

DESCRIPTION OF BUSINESS

Sunwin Stevia International, Inc., a Nevada corporation, and its subsidiaries are referred to in this report as “we”, “us”, “our”, or “Sunwin”.

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines and veterinary products. Substantially all of our operations are located in the People’s Republic of China (the “PRC”). We have built an integrated company with the sourcing and production capabilities designed to meet the needs of our customers.

Our operations are organized into two operating segments related to our Stevioside and Chinese Medicine product lines.

In June 2010 we elected to streamline our product offerings to focus on our core business of producing and selling stevia and other herb-based products, including herb extracts and herb medicines.  Consequently, we have exited all business activities related to our veterinary medicines and sold our 100% interest in our Shengya Veterinary Medicine subsidiary to Mr. Laiwang Zhang, our President and Chairman of the Board of Directors on July 31, 2010.  

Name change

We changed our name from Sunwin Neutraceuticals International Inc. to Sunwin Stevia International, Inc. on April 23, 2012 to more accurately reflect our business operations.

Stevioside Segment

Stevioside, whose content includes rebaudioside, is an all natural, low calorie sweetener extracted from the leaves of the stevia rebaudiana plant.  Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets.

Chinese Medicine Segment

In our Chinese Medicine Segment, we manufacture and sell a variety of traditional Chinese medicine formula extracts which are used in products made for use by both humans and animals.

Qufu Shengwang

In fiscal 2009, Qufu Natural Green acquired a 60% interest in Qufu Shengwang from its shareholder, Shandong Group, for $4,026,851. The purchase price represented 60% of the value of the net tangible assets of Qufu Shengwang as of April 30, 2008. Shandong Group is owned by Laiwang Zhang, our President and Chairman of the Board of Directors.  Qufu Shengwang manufactures and sells stevia -based fertilizers and feed additives.

On September 30, 2011, Qufu Shengwang purchased the 40% equity interest in Qufu Shengwang owned by our Korean partners, Korea Stevia Company, Limited, for $626,125 in cash, and as a result of this repurchase transaction we now own 100% equity interest in all of the net assets of our subsidiary Qufu Shengwang. Therefore, the non-controlling interest of $2,109,028 in our balance sheet as of April 30, 2012 has been eliminated to reflect our 100% interest in Qufu Shengwang. We plan to use these assets to produce bio-bacterial fertilizers from our stevia residues along with the strain and formula provided by our cooperation partner Beijing Hegeng Organic Farm Technology Co., Ltd (“Hegeng”). Our facility has an estimated annual capacity to produce 10,000 metric tons of bio-bacterial fertilizers. We expect to start production in fiscal 2013.

Qufu Shengren

In fiscal 2009, Qufu Natural Green acquired Qufu Shengren for $3,097,242. The purchase price was equal to the value of the assets of Qufu Shengren as determined by an independent asset appraisal in accordance with asset appraisal principles in the PRC. Prior to being acquired by us, Qufu Shengren was engaged in the production and distribution of bulk drugs and pharmaceuticals.  Subsequent to the acquisition, Qufu Shengren produces and distributes steviosides with a full range of grades from rebaudioside-A 10 to 98.

Sunwin USA

In fiscal 2009, we entered into a distribution agreement with WILD Flavors to assist our 55% owned Sunwin USA in the marketing and worldwide distribution of our stevioside based sweetener products and issued WILD Flavors a 45% interest in Sunwin USA.  In exchange WILD Flavors agreed to provide Sunwin USA with sales, marketing, logistics and supply chain management, product development and regulatory services valued at $1,000,000 over a period of two years beginning on February 5, 2009.

On August 8, 2012 we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541.  The transaction closed on August 20, 2012.  On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors. The $92,541 cash payment was paid by CDI and reimbursed by us through shares as part of the terms in the consulting agreement with CDI dated May 1, 2012. The net tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of generally accepted accounting principles (“U.S. GAAP”) which require elimination of the difference between the purchase price of 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets include the product development and supply chain for onlysweet.

Under the terms of the agreement, WILD Flavors assumed certain pre-closing obligations of Sunwin USA totaling approximately $694,000, including trade accounts receivable, loans, health care and monthly expenses of an employee, potential chargebacks, bank fees and broker commissions incurred prior to the closing date.  The agreement also contained customary joint indemnification and general releases.  As a result of this transaction, we will begin consolidating the operations of Sunwin USA with ours from the date of acquisition (August 20, 2012).

In addition to the Exchange Agreement, on August 8, 2012 we entered into the following additional agreements with WILD Flavors or its affiliate:

-           We entered into an Amendment to Operating Agreement with WILD Flavors pursuant to which we are now the sole manager of Sunwin USA and certain sections of the original agreement dated April 29, 2009 were deleted as they were no longer relevant following our purchase of the minority interest in Sunwin USA described above;

-           We entered into a Termination of Distribution Agreement with WILD Flavors and Sunwin USA pursuant to which the Distribution Agreement dated February 5, 2009 was terminated; and

-           We entered into a Distributorship Agreement with WILD Procurement Gmbh, a Swiss corporation (“WILD Procurement”) which is an affiliate of WILD Flavors.  Under the terms of this agreement, we appointed WILD Procurement as a non-exclusive world-wide distributor for the resale of our stevia products.  There are no minimum purchase quantities under the agreement, and the pricing and terms of each order will be negotiated by the parties at the time each purchase order is placed.  The agreement restricts WILD Procurement from purchasing steviosides or other forms of stevia that are included in our products from sources other than our company under certain circumstances.  In addition, at such time as we desire to offer new products, we must first offer WILD Procurement the non-exclusive right to distribute those products and the parties will have 60 days to reach mutually agreeable terms.  The agreement contains certain representations by us as to the quality of the products we may sell WILD Procurement and the products’ compliance with applicable laws and good manufacturing practices, as well as customary confidentiality and indemnification provisions.

In the event WILD Procurement should fund research on stevia used in food, beverage or dietary supplement applications, and as a result of this research it develops new intellectual property, such intellectual property shall be the sole property of WILD Procurement.  In the event we should jointly fund research, any new intellectual property developed from this effort will be jointly owned and each party will have the right to use the developed intellectual property in stevia-based products.

The agreement is for an initial term of 12 months and will automatically renew for successive 12 month terms unless the agreement has been terminated by either party upon 45 days prior written notice.  There are no assurances any purchase orders will be placed under the terms of the Distribution Agreement.  The agreement may also be terminated by either party upon a material breach by the other party, or upon the filing of a bankruptcy petition, both subject to certain cure periods.  In the event the agreement is terminated, WILD Procurement has the right to continue to distribute our products on a non-exclusive basis for 24 months upon terms and conditions to be negotiated by the parties.

XML

Note 6 - Intangible Assets

3 Months Ended

Oct. 31, 2012

Note 6 - Intangible Assets:

Note 6 - Intangible Assets

NOTE 6 – INTANGIBLE ASSETS

Intangible assets consisted of the following:

	Estimated Life	October 31, 2012	April 30, 2012
		(unaudited)
Intangible assets, gross	5 years	$   1,625,874	$                    -
Less: Accumulated Amortization, Intangible assets		(54,196)	-
Intangible assets		$   1,571,678	$                    -

Due to our acquisition of the remaining 45% interest of Sunwin USA originally by Wild Flavors (See Note 1), we acquired intangible assets which included the supply chain developed by Wild Flavors. For the six months ended October 31, 2012 and 2011, amortization expense amounted to $54,196 and $0, respectively.  

XML

Note 6 - Intangible Assets (Details) (USD $)	6 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Amortization of Acquired Intangible Assets	$ 54,196	$ 0

XML

Note 13-commitments and Contingencies (Details) (USD $)	Dec. 08, 2011	Aug. 25, 2011
Purchase price for apartment units held for sale		$ 2,390,325
Payment of purchase price for apartment units held for sale	1,195,162	717,097
Remaining balance of purchase price for apartment units held for sale	$ 478,066

XML

Note 2- Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)

3 Months Ended

Oct. 31, 2012

Fair Value of Financial Instruments:

Fair Value of Financial Instruments

FAIR VALUE OF FINANCIAL INSTRUMENTS

We follow the FASB ASC Section 825-10-50-10 for disclosures regarding the fair value of financial instruments and have adopted ASC Section 820-10-35-37 to measure the fair value of our financial instruments. ASC Section 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC Section 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.

ASC Section 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Section 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.  

With the exception of derivative liabilities, we do not have any other assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at October 31, 2012 and April 30, 2012, nor were any gains or losses reported in the statement of operations that were attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the year then ended.

XML

Note 6 - Intangible Assets: Schedule of Intangible Assets and Goodwill (Tables)

3 Months Ended

Oct. 31, 2012

Schedule of Intangible Assets and Goodwill:

Schedule of Intangible Assets and Goodwill

	Estimated Life	October 31, 2012	April 30, 2012
		(unaudited)
Intangible assets, gross	5 years	$   1,625,874	$                    -
Less: Accumulated Amortization, Intangible assets		(54,196)	-
Intangible assets		$   1,571,678	$                    -

XML

Note 2- Summary of Significant Accounting Policies: Use of Estimates (Policies)

3 Months Ended

Oct. 31, 2012

Use of Estimates:

Use of Estimates

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant estimates include the estimated useful lives of property and equipment, the allowance for doubtful accounts.  Actual results could differ from those estimates.